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1 Introduction 
 
 
1.1 Central nervous system 
 
The CNS of vertebrates consists of the brain, spinal cord and retina. The brain is made up of 
extensive and complex networks of neurons and their supporting cells termed as glial cells. 
Neurons are interconnected by synaptic junctions and are involved mainly in conduction of rapid 
action potential signals along their axons. Compared to neurons, glial cells are more abundant in 
the CNS i.e., accounting for approximately 65% of cells in rodent brain and 90% in humans 
(Pfrieger und Barres, 1995). Virchow in 1846 for the first time described glial cells as neuroglia 
and later they were more extensively described by Ramon y Cajal and Rio-Hortega in 1913. 
Glial cells are predominantly involved in supporting neurons and maintaining metabolic 
homeostasis in the CNS. They are broadly classified into astrocytes, oligodendrocytes, and 
microglia, based on their functional significance. Glial cells including astrocytes and 
oligodendrocytes are derived from ectodermal tissue of the developing embryo, whereas 
microglial cells are derived from hematopoietic precursors. 
Astrocytes are star shaped cells and are majorly populated among the glial cell population within 
the brain. They are distributed in the grey and white matter of the brain. Immature astrocytes are 
called radial glia, which play a major role in neuronal migration during fetal development. 
Astrocytes are mainly involved in regulating the external chemical environment in the brain such 
as recycling neurotransmitters released during synaptic transmission, and also provide growth 
factors to neurons. Astrocytes contact blood capillaries and the nodes of Ranvier (Figure 1) and 
are also involved in angiogenesis (Montgomery et al., 1994). Microglia functions as brain 
macrophages of the CNS and account for 15% of total glial cells. They are mainly involved in 
phagocytosis (Compston et al., 1997) and are typically in the resting state and are activated 
under conditions like CNS inflammation, trauma, and infections. Microglial cells are the resident 
macrophages in the brain. Oligodendrocytes are involved in the myelination of axons in the 
CNS, whereas Schwann cells are involved in PNS.      
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Figure 1: Neuron and glial cells in the brain. Left; Oligodendrocytes wrapping myelin sheath around 
neuronal axons, astrocytes are attached to blood capillaries, neurons and microglial cells, Right; 
Individual glial cells i.e., astrocytes, microglia and oligodendrocytes (modified from MHHE science 
resource) 
 
1.2 Oligodendrocytes   
 
Rio-Hortega first described oligodendrocytes and microglia in 1928. Like neuronal progenitors, 
early oligodendrocytes progenitors are derived from neuroepithelial precursors of the ventricular 
zone of the brain and lumen of the spinal cord (Reynolds and Wilkin, 1988; Levine and 
Goldman, 1988). Mature oligodendrocytes develop from their early progenitors broadly in four 
stages i.e., early progenitor cells (O2A cells), late progenitor cells (A2B5, O4 cells), premature 
oligodendrocytes and mature oligodendrocytes (Figure 2). All these differentiation stages 
undergo several morphological changes starting from single or bipolar to multiple projections, 
and express cell specific antigen markers such as NG2, O4, GalC, MBP, and PLP (Figure 2) 
along with several other intracellular changes (Wia Baron, 2003). The early glial progenitors 
exhibit lineage plasticity such as neural stem cell like features of differentiation into neuronal or 
any of the glial cell types (Kondo and Raff, 2000c), whereas O4 progenitors (OL-progenitors) 
are the start of the committed oligodendrocyte lineage. Immature-oligodendrocytes express 
galactocerebrosides and other myelinating proteins such as MBP and Dm20 which are 
transported and enriched at the filopodial-like projections of the plasma membrane, whereas they 
are not capable of myelinating axons.  Pre or mature-oligodendrocytes are involved in 
myelinating axons with their plasma membrane derived filopodia-like structures.  
Oligodendrocytes are also capable of expressing myelin genes and develop filopodia-like 
projections in the devoid of external neuronal signals under in vitro conditions (Pfeiffer et al., 
1993).  
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Figure 2: Developmental stages of oligodendrocytes from early progenitors. Different cell specific 
gene markers expressed during oligodendrocyte maturation; OL=Oligodendrocyte. (Modified from Back 
SA et al., 2007)  
 
 
1.2.1 Targeting of myelin components in oligodendrocytes 
 
Oligodendrocytes have highly specialized mechanisms for sorting and targeting myelin protein 
and lipid components to the growing polarized plasma membrane/myelin membrane. 
Oligodendrocytes share similarities with polarized epithelial cells, such as MDCK cells, in the 
underlying mechanisms of protein trafficking to the plasma membrane (Kramer et al., 2001). 
Polarized cells like MDCKs are therefore suitable in vitro cell culture models for studying the 
underlying mechanisms of myelin proteins trafficking. For instance, transfection studies in 
MDCK cells showed differential trafficking among myelin proteins; PLP is sorted to the apical 
membrane and MOG sorted to the basolateral membrane (Kroepfl and Gardinier, 2001). Among 
the two isoforms of MAG i.e., S-MAG and L-MAG, L-MAG is targeted to both apical and 
basolateral compartments, whereas S-MAG is targeted only to the apical domain (Minuk and 
Braun, 1996).  
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In oligodendorcytes, PLP is transported from the ER to the cell surface via mechanisms 
including vesicular transport, endosome, and transcytosis. Polarized trafficking of myelin 
proteins and lipids, such as PLP and GalC, may include initial sorting at trans-Golgi or in 
endosomes accordingly and then transported to specific plasma membrane domains directly or 
via cytoskeleton anchored transport in a spatial and temporal manner. MBP and MOBP’s mRNA 
isoforms are transported near to the plasma membrane where actually their protein translation is 
initiated (Barbarese et al., 1995). CNP is transported anchored to the cytoskeleton, such as actin 
filaments and microtubules, to the non-compact myelin membrane regions (Laezza et al., 1997). 
The exact trafficking routes of myelin components, especially mutated myelin proteins, and their 
mechanisms of plasma membrane targeting are still under investigation.  
 
 
1.2.2 Nestin and MBP expression 
 
Nestin protein is an intermediate filament protein that is specifically expressed in neural tube, 
neuroepithelium stem cells and in glial precursors (Lendahl et al., 1990). Nestin is also expressed 
in neural stem cells and in its subsequent generations of neuronal progenitors and glial 
progenitors (Zimmerman et al., 1994, Johansson et al., 2002). In the oligodendroglial lineage, 
nestin expression levels are gradually down-regulated from immature-oligodendrocyte to mature 
oligodendrocytes (Vittorio Gallo and Regina C Armstrong, 1995). The nestin gene contains four 
exons and three introns and is highly conserved among human, rat and mouse (Lendhal U et al., 
1990; Lothian et al., 1999). The second-intron enhancer of the nestin gene is particularly critical 
as it contains regulatory elements proposed to regulate gene expression specifically in the neural 
stem cells and in subsequent oligodendrocyte progenitors (Zimmermann et al., 1994, Lothian et 
al., 1999). 
Of the two major myelin proteins synthesized in oligodendrocytes, PLP and MBP, MBP has a 
stronger promoter for transcription initiation than PLP. 1.5kb of intron-I and partial-exon-I of 
MBP gene sequence containing the MBP promoter has been well characterized in a transgenic 
mouse mutant (Kimura et al., 1989).  Although MBP is a marker for mature-oligodendrocytes, 
an MBP isoform is also detected in early embryonic developmental stages, on both the protein 
and mRNA level, and is called embryonic-MBP or E-MBP (Mathisen et al., 1993; Nakajima et 
al., 1993). As characterized in wild-type mice, E-MBP expression is observed in early 
embryonic stages, postnatal day-7, day-20 (active-myelination phase) and day-60 (matured-
myelination phase) (kimura et al., 1989).  
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1.3 CNS Myelin   
 
Myelin has been first described and termed by Rudolf Virchow in 1854 and its ultra structure 
first studied by Sjoestrand in 1947 by electronic microscopy. Myelin is a highly regulated plasma 
membrane extension of oligodendrocytes in the CNS, and Schwann cells in the PNS. In the CNS, 
the plasma membrane of oligodendrocytes or myelin is spirally wrapped around the axons of 
neurons in multiple locations termed internodes (Figure 3.A). Periodic interruptions between two 
internodes that leave the axon unmyelinated are termed nodes of Ranvier (N), and the edges of 
the internode are termed paranodes (PN) (Figure 3 C, B).  
 
Internodes and myelin compaction  
 
Spirally wrapped internodal myelin layers are compacted due to van der Waals, and electrostatic 
forces between polar head groups of phospho- and sphingolipids, as well as interactions of 
phospholipids with cytosolic MBP and integral membrane proteins such as PLP. In electron 
micrographs myelin layers appear as periodic structures of electron dense lines termed major-
dense lines (MDL) and less electron-dense lines termed intraperiod lines (IPL) (Figure 3.D). 
MDLs represent the tight opposition of cytoplasmic sides while IPLs represent the extracellular 
side of the myelin membrane. Myelin proteins such as PLP, MAG and MOG are integrated into 
the cholestrol-phospho- and sphingolipid bilayer of the myelin membrane (Figure 3D). The 
periodicity distance between two IPL is 170 ± 7 Å. Occasionally the compact cytoplasm, i.e. 
MDL, is interrupted and compaction is lost, forming funnel like longitudinal structures along the 
MDL, called Schmidt-Lanterman clefts however these are very rare in CNS and more abundant 
in PNS.   
 
Paranodes and junctions 
 
Paranodes are the end points of internode (Figure3 C, B). The periaxonal space of the myelin is 
sealed from the outside milieu and connected to the axon via septate-like junctions (Einheber et 
al., 1997; Saher et al., 2011) (Figure 3B). The paranodal loops or junctions are connected with 
the axons by tight junction proteins such as OSP or Claudin-11 (Figure 3 B). Paranodal junctions 
are critical for efficient action potential propagation and in ion channel clustering (Schafer et al., 
2004). The outer most part of paranode is termed juxtaparanodal (JPN) region.  
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Nodes of Ranvier 
 
Louis-Antoine Ranvier discovered regularly spaced unmyelinated gaps (approximately 1 µm in 
length) termed nodes of Ranvier (Figure 3.B). They harbor voltage-gated sodium (Na+) ion 
channels that are engaged in conduction of action potentials. Myelinated axons have salutatory 
conduction in the range of 1 m/s to over 100 m/s, 0.5m/s to 15 m/s in unmyelinated axons 
(Mutschler, 1991), thus enhancing the conductance 10-fold compared to unmyelinated axons. 
 
 
Figure 3: Schematic representation of CNS myelin. A. An oligodendrocyte myleinating multiple 
axons. B. Zoomed view depicting paranaodal junction and its molecular arrangement C. Zoomed view 
representing node of Ranvier (N), paranodal junction (PN) juxtaparanodal junction (JPN) and internode 
(INT), and D. Zoomed view of myelin membrane extracellular side and cytoplasmic arrangement, 
intraperiod lines (IPL), myelin dense line (MDL), and embedded myelin proteins in the myelin 
membrane. (Adapted and modified from Potter et al., 2010) 
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Myelin proteins  
 
Myelin accounts for 30% of the dry weight of the brain. Myelin is a lipid rich membrane, with 
70-80% lipids and 20-30% proteins. The myelin membrane is composed of unusual sphingolipid 
classes and high cholesterol and myelin specific proteins.  
The most abundant proteins of myelin are proteolipid protein (PLP) and myelin basic protein 
(MBP) constituting 50% and 30%, respectively, together making 80% of whole myelin protein 
composition. PLP and MBP localization in the myelin membrane was first identified based on 
immunolocalization studies (Hartman et al., 1982). Other myelin proteins are: 2’, 3’-cyclic 
nucleotide-3‘-phosphodiesterase (CNP) 4-5%, myelin associated glycoprotein (MAG) 1%, and 
myelin oligodendrocyte glycoprotein (MOG) and myelin-oligodendrocyte basic protein (MOBP) 
>1% each (S. A. Kalwy and Ross Smith, 1994). Recently several hundreds of distinct proteins of 
low range concentrations were detected in the myelin through gel based proteome analysis 
(Werner et al., 2007).  
 
Proteolipid protein (PLP) is further discussed in section 1.4.  
 
Myelin basic protein (MBP) 
 
MBP has several splice variants which differ in different species, four in humans, and six in 
mice, with protein sizes ranging from 14 to 24kDa (Newman et al.,1987). MBP contains a high 
number of basic amino acid residues and is a hydrophilic protein localized in the cytoplasm of 
the myelin membrane (MDL) (figure 3 D). As MBP is highly positively charged, it may interact 
with the cytoplasmic side myelin membrane, thereby contributing to compaction and 
stabilization of the myelin membrane (Figure 3 D) (Morell et al., 1994). Although MBP null 
mice (shiverer mutant or myelin deficient mutants) show compact myelin around the axons, its 
hypomyelination causes severe neurological defects including tremors and seizures (Bird et al., 
1978). Several types of post-translational modifications occur on MBP such as acetylation, 
phosphorylation, methylation and citrullination (Wood and Moscarello, 1989). Futhermore 
methylation of MBP might be important for compaction of myelin sheath (Campagnoni et al., 
1993). MBP is also present in PNS which accounts for 5-15 % of total proteins. 
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Myelin-associated glycoprotein (MAG)  
 
MAG is an integral membrane glycoprotein with a molecular mass of 100 kDa. It has two 
isoforms; L-MAG and S-MAG. MAG is involved in axon-glial contacts and signaling, and 
axonal maintenance (Poltorak et al., 1987). The majority of MAG is located in periaxonal 
regions of myelin (Webster et al., 1983). Its structural role in the myelin sheath is not clear. 
 
Myelin-oligodendrocyte glycoprotein (MOG) and other proteins  
 
MOG is an integral membrane glycoprotein which was first identified as one of the antigens in 
experimental autoimmune encephalomyelitis (EAE). MOG is highly glycosylated and is believed 
to act as an adhesion molecule. MOG is also involved in signal transduction pathways, and lipid-
protein sorting (Kim and Pfeiffer, 1999).  
Other myelin proteins such as: CNP is located in the cytoplasm and one of the earliest expressed 
proteins during myelination. Although CNP is named after its function and believed to have a 
structural role, its functional role in CNS remains to be elucidated. Adult CNP null mice showed 
axonal swellings and axonal degeneration. The double mutant plp-/-cnp-/- mice showed 
progressive axonal loss (J.M. Edgar et al., 2009). Other myelin proteins such as myelin-
associated oligodendrocytic basic protein (MOBP) and tight junction proteins like 
oligodendrocyte specific protein (OSP)/Claudin-11 are minor components among myelin 
proteins with undefined functions. Due to various transgenic mouse mutants, it is now clear that 
the tight junction proteins including OSP protein are important in proper CNS myelination and 
function.  
 
Myelin proteins and respective phenotypes 
 
Myelin is a complex unique membrane, and many proteins are specific to myelin. Many studies 
have been made during the past two decades also by employing transgenic mice. Various myelin 
proteins, respective knockout mouse mutants, and their phenotypes are summarized in the table 
1.  
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Myelin Protein Location and function Null-mouse  mutants and 
their myelin phenotype 
PLP/Dm20 
(Hydrophobic and 
Integral membrane 
spanning protein) 
Localized to myelin membrane 
internodes, involved in myelin 
compaction and long term axonal 
stabilization. 
Loss of myelin compaction 
(Dissociation of outer 
surface, IDL); Late onset of 
axonal degeneration (Boison 
and Stoffel, 1994; Griffiths 
et al., 1998) 
MBP 
(Hydrophilic and 
Peripheral membrane 
protein) 
Localized in cytoplasm (MDL), 
and  might be also involved in 
compaction of myelin 
Hypomyelination but myelin 
remains compact, Increased 
number of oligodendrocytes 
(Bird et al., 1978; Nagara et 
al.,1983) 
MAG 
(Glycoprotein and 
Integral membrane 
protein) 
Present at periaxonal membrane, 
and involved in maintenances of 
periaxonal collar  
Reduced cytoplasmic collar, 
multiple myelin sheaths 
(CNS). (Li et al., 1994) 
 
CNP 
(Membrane associated 
protein) 
Localized to cytoplasmic channels, 
paranodal loops, and axon-glial 
interactions 
Early axonal degeneration 
(Lee et al., 2005; Rasband et 
al., 2005) 
 
OSP/Claudin11 
Integral membrane 
protein, and belongs to 
claudin tight junction 
protein family 
Majorly localized to paranodal 
septet junctions and radial 
compartment 
Loss of tight junctions at 
paranodal loops, and mild 
motor impairments  
(Gow et al.,1999) 
 
Table 1: Summary of the major myelin proteins and their functional significance in myelin 
 
 
1.4 CNS Myelin; Proteolipid Protein (PLP) 
 
In 1951 Folch and Lees isolated PLP, the major protein accounting approximately 50% of total 
brain myelin protein. PLP cDNA has been cloned in 1986 in our laboratory (Schaich et al., 
1986). 
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1.4.1 PLP gene transcripts and isoproteins 
 
The PLP (plp1) gene is 16 kb (Diehl et al., 1986) and is located on the X-chromosome, Xq22 in 
human and H2C in mice. The PLP gene is comprised of seven exons (Diehl et al., 1986; Stoffel 
et al., 1985) and has a protein coding region of 828 bps that encodes 276 amino acids (Stoffel et 
al., 1982). PLP has a splice variant called Dm20. Dm20 mRNA lacks the last 105 bps of exon 3 
of PLP mRNA and thereby 35 amino acids in the cytosolic loop of PLP (Nave et al., 1987). PLP 
is expressed primarily in oligodendrocytes where it is integrated into the plasma membrane. PLP 
has been extensively studied for more than 20 years, on the molecular and structural level, and 
regarding its role in myelin morphology specifically in relation towards CNS myelin disorders. 
PLP is highly conserved. Specific point mutations in PLP result in the severe form of Pelizaeus–
Merzbacher disease (PMD) (Weimbs et al., 1990) or spastic paraplegia type 2 (SPG2) (Koeppen 
and Robitaille, 2002), whereas the absence of PLP does not result in PMD nor in myelin defects 
but only in loss of myelin compaction (Boison and Stoffel., 1994) and axonal degeneration in 
adults (Griffith et al., 1998). Strikingly, the wild-type PLP gene over-expression in mouse 
models (i.e., PLP transgenic mouse model) revealed that PLP over-expression alone imparts 
toxicity in the oligodendrocytes and thus causes myelin defects that could result in PMD 
condition, demonstrating the importance of PLP gene dosage (Karim et al., 2007).  
In addition to the classical PLP and its isoform Dm20, Bongarzone et al., 1999 showed an 
additional exon and translational site between exon-I and exon-II of the classical PLP gene. The 
derived mRNA can also be alternatively spliced into two new isoforms called sr.PLP and 
sr.Dm20. Their corresponding protein products contain an additional 11 amino acids. These 
novel isoforms (i.e., sr.PLP and sr.Dm20) accounts to 2% of total myelin protein composition, 
restricted to the somata of oligodendrocytes and neurons, and not detected nor trafficked to the 
myelin membrane.  
 
Structure and Protein conservation 
 
PLP is the highly hydrophobic and integral transmembrane protein of the myelin membrane. The 
complete topology of PLP was unraveled by biochemical studies by Weimbs and Stoffel, 1992 
and Wahle and Stoffel, 1998. PLP contains four transmembrane spanning hydrophobic domains 
connected by three hydrophilic loops in which two loops (EC-I and EC-II) are located in the 
extra-cytosolic space and one loop in the cytosolic space. The NH2 and COOH terminal domains 
are located on the cytosolic side (Weimbs and Stoffel, 1992; Gow et al., 1994; Greer et al., 
1996). PLP is phylogenetically highly conserved (Schliess and Stoffel, 1991), and is identical at 
amino acid level among human, mice and rat (Figure 4). PLP from birds and amphibians also 
show approximately 85% homology with mammalian PLP (Schliess and Stoffel, 1991). PLP and 
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Dm20 and other proteins such as M6 glycoproteins share, to a certain extent, homology in their 
transmembrane domains and Cys positions (Greer et al., 2001). PLP amino acid residues are 
conserved especially with regard to their point mutations among mammals and other species 
(Schliess and Stoffel, 1991).  
 
 
1.4.2 Cys residues and hydrophobic properties 
 
Of fourteen Cys residues in PLP, six at amino acid positions 5, 6, 9, 108, 138 and 140 are 
involved in post-transacylation modification, four Cys residues are involved in formation of 
disulfide bridges i.e., Cys183-Cys227 and Cy200-Cys219, and the remaining four Cys residues 
at amino acid positions 24, 32, 34 and 168 are located in the hydrophobic domains in the myelin 
membrane (Weimbs and Stoffel, 1992; Wahle and Stoffel, 1998). 
PLP is also soluble in organic solvents such as chloroform/methanol due to its strong 
hydrophobic nature. It is composed of more than 50% of apolar (hydrophobic) residues that are 
spanned in the phospholipid bilayer as four hydrophobic membrane domains (Wahle and Stoffel, 
1998; Stoffel et al., 1984; Weimbs and Stoffel, 1992). PLP also undergoes post-translational 
modification i.e., acylation where fatty acid (usually palmitic acid) is covalently bound to thiol 
groups of Cys residues of PLP. Acylated fatty acids of PLP might interact with the adjacent 
myelin phospholipid bilayer and also contribute to the hydrophobic nature of PLP (Weimbs and 
Stoffel, 1992). Alterations in PLP such as point mutations, deletions, duplication, missense 
mutation, over-expressions lead to disturbance in the PLP topology or conformation and 
abnormal targeting in oligodendrocytes. PLP misfolding may result in oligodendrocytes 
apoptosis and thus myelin disorders such as PMD and SPG2. 
Multi-alignment of human, mouse and rat’s PLP CDNA sequence 
   
Figure 4: Alignment of human, mouse and rat protein sequences. 100% homology (consensus) is     
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observed among human (H.sapiens), mouse (M.musculus), and Rat (R. norvegicus) on protein sequence. 
‘Align’ software was used for alignment and respective protein sequences were obtained from ensemble 
database.  
 
                 
 
Figure 5: Topology of proteolipid protein (PLP) and its isoform Dm20. Dm20 lacks 35 amino acids 
from 116 to 150 in the hydrophilic loop of PLP (absence of violet color dashed line).  PLP/Dm20 contains 
four hydrophobic membrane spanning domains, one intracellular and two extracellular loops, two 
disulphide bridges in the extra-cytosolic-II loop and post-translational modifications (transacylation on 
Cys residues). 
 
Point mutations, disulfide bonds, and cell surface targeting 
 
PLP/Dm20 is synthesized in oligodendrocytes on membrane bound polysomes and via Golgi 
vesicular transport it is targeted to the plasma membrane. Calnexin, an ER chaperone, binds to 
the newly synthesized PLP in the ER and contributes in its proper folding and ER quality control 
(Swanton et al., 2003). Properly folded PLP exits the ER and interacts with lipid rafts for 
vesicular transportation to the cell surface, whereas misfolded PLP (due to point mutations) is 
stably coupled with calnexin and does not exit the ER. Moreover stable binding of PLP with 
calnexin chaperone further prohibits ER-protein degradation, thus accumulating PLP in the ER, 
causing ER stress and further triggering apoptosis via unfolded-protein response (UPR), which in 
turn may lead to PMD or SPG2. The impairment of the PLP association with lipid rafts, due to 
its misfolding, might perturb its normal transport leading to a condition called as SPG2 
(kraemer-albers et al., 2006). If PLP is in excess quantity, as in the case of PLP duplications, 
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during its intracellular transport excess PLP constituting lipid rafts are trapped in the lysosome 
which triggers oligodendrocyte apoptosis, a situation observed in dysmyelination (Simons et al. 
2002). In less severe forms of PMD or SPG2, PLP is trapped in the ER, but its isoform Dm20 is 
targeted normally to the cell surface, indicating that PLP and Dm20 are differentially targeted, 
which correlates with the extent of  PMD pathology. 
The proximal (Cys183-Cys227) and outer disulphide bridges (Cys200-Cys219), located in EC-II 
loop of PLP/Dm20 are critical in trafficking. Their functional role under in vivo conditions 
specifically in cell surface trafficking of PLP/Dm20 and in myelin phenotype is still unknown. In 
the heterologous COS-7 cells of in vitro system, PLP, lacking the proximal disulphide bridge, is 
retained in the ER and is not detected on the cell membrane. Therefore the proximal disulphide 
bridge is involved in ER quality control. In contrast, PLP lacking the outer disulphide bridge 
passed ER quality control and appeared on the cell membrane similar to the wild-type PLP. 
Therefore the outer disulphide bridge is not involved in ER quality control. PLP devoid of both 
disulphide bridges is ER retained (Dhaunchak and Nave, 2007). Interestingly, there is also a 
human case report demonstrating naturally occurring point mutation at Cys219Tyr deleting the 
outer disulfide bridge of PLP. This point mutation traps PLP in the ER and expresses the 
connatal PMD phenotype (Fukumura et al., 2010). 
 
 
1.4.3 PLP related myelin disorders; PMD and SPG2  
 
Naturally occurring mouse mutants such as rumpshaker mouse containing a point mutation 
(I186T) in PLP (Schneider et al., 1992), Jimpy mouse mutant with an A242V point mutation in 
PLP, and a PLP transgenic mouse with extra PLP copies (Redhead et al., 1994), exhibited severe 
myelin defects such as dysmyelination and hypomyelination. Some of these myelin defects 
resulted in PMD or SPG2 diseases. The main molecular mechanism that underlies PMD and 
SPG2 is impaired targeting of PLP to the oligodendrocyte plasma membrane (Seitelberger, 1995; 
Werner et al., 1998) and oligodendrocyte apoptosis. The different trafficking of PLP and Dm20 
in oligodendrocytes is also a determining factor influencing PMD severity. Both isoforms, when 
retained in the ER, result in severe forms of connatal PMD. When PLP alone is retained in the 
ER and Dm20 is targeted normally to the oligodendrocyte cell surface a less severe or classical 
form of PMD is observed (Gow and Lazzarini, 1996).  
PMD or SPG2 mouse models exhibit phenotypes such as neuromotor defects including leg and 
arm muscle atrophy, seizures, tremors, cognitive and behavioral defects. They die prematurely 
within few weeks after birth (Yool et al., 2000). The PMD mouse models closely resemble 
human PMD on the molecular level, such as mutations in PLP. PMD patients exhibit mild to 
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severe abnormalities starting from their first postnatal year with gradual progression; delayed 
cognitive development, spasticity or muscle weakness, partially controlled neck and head 
movements and involuntary eye moments. Patients with the severe form of SPG2 exhibit defects 
in motor development including partial extent of cognitive defects of PMD. 
 
                           
 
Figure 6: PLP with some of the point mutations which lead to PMD/SPG2. Children effected with 
PMD, and the severely affected PMD (PLP jimpy, A242V) mouse model. (Pictures adapted and modified 
from Grossi et al., 2011, CURE-PMD organization). 
 
 
1.5 CNS Myelin; Phospho- and sphingolipids 
 
Lipids constitute 70% of the total CNS myelin dry mass, with galactocerebrosides (GalC) being 
the most abundant lipid class. Major lipid types in the whole brain and in myelin (white matter) 
are cholesterol, phospholipids, and glycosphingolipids which are present in a ratio of 4:3:2 
(Norton and Cammer, 1984). Phospholipids of myelin contain 70% phosphatidylethanolamine as 
plasmalogens compared to 5% in liver. Phospholipids are asymmetrically distributed in the 
myelin membrane; wherein mostly phosphoglycerides are arranged in the cytoplasmic leaflet of 
myelin MDL and galactosphingolipids (GalC and sGalc) at the exoplasmic face of the myelin 
IDL (Figure 3.D). The important role of lipids and proteins in the myelin membrane was verified 
by several in vivo and in vitro experiments (Table 2).  
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Targeted myelin lipid Disrupted enzyme Myelin morphology and 
phenotypes in various null 
mouse mutants 
GalC and Sulfatides (Sulfated 
GalC)  
(Bosio et al.,1996) 
UDP-galactose-ceramide 
galactosyltransferasae (CGT) 
Perturbed myelin membrane 
paranodal loops and septate 
junctions. Impaired salutatory 
conduction. Showed sever 
neurological defects 
Sulfatides  
(Honke et al., 2002) 
Cerebroside sulfotransferase 
(CST) 
Perturbed myelin paranodal 
loops. Similar but with less 
sever phenotypes to that of CGT 
null mutant. 
Hydroxyl-fatty acid-GalC and  
Hydroxyl-fatty acid- 
Sulfatides  
Fatty Acid 2-hydrolase 
(FA2H) 
Late onset of myelin 
degeneration  and myelin de-
compaction 
Cholesterol 
(Saher et al., 2005) 
Squalene synthase in 
oligodendrocytes of mice 
Myelination defects 
 
Table 2: Important lipids of myelin, their enzymes, and their role in myelin morphology   
 
 
The retina, a highly organized CNS structure, is rich in phospholipids and is essential for visual 
functions. Phospholipids of retina consists 54% of phosphatidylethanolamine (PE) and 30-40% 
phosphatidylcholine (PC), which constitutes mainly PUFA at both sn1 and sn2 positions. 
Impairment in PUFAs composition may alter visual function. Retina morphology and function, is 
further discussed in section 1.5.4. 
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1.5.1 Fatty acid composition of phospholipids 
 
Phosphoglycerides have a glycerol backbone, and sphingolipids have a sphingosine back bone. 
In phosphoglycerides; two fatty acids, generally a saturated and an unsaturated or 
polyunsaturated fatty acid (PUFA), are bound as esters at the sn-1 and sn-2 of the glycerol 
backbone. In sphingolipids; only single fatty acid chain, generally a saturated or un- or 
polyunsaturated, is linked with an amide bond to the sphingosine back bone. In 
phosphoglycerides, a polar head group such as choline, ethanolamine, serine and inositol, is 
linked by a phosphate ester bond to a third carbon (C3) of the phosphoglyceride back bone. 
Thus, based on the type of polar head group attached, the phosphoglycerides are termed 
accordingly as phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, and 
phosphatidylinositol. Sphingolipids contain polar head groups such as phosphocholine in 
sphingomyelin, and glucose or galactose polar head groups in cerobroside (GluC/GalC). 
The basic structure of membrane phospholipids is depicted in the figure 7.  
The appropriate nature and composition of saturated and unsaturated or polyunsaturated fatty 
acids in phospholipids of cell membranes are critical in maintaining respective membrane 
conformation, stability, fluidity and dynamics. Besides structural roles, fatty acids also serve in a 
variety of functions such as energy reserves, precursors of eicosanoids, and regulators of myelin 
gene expression in the brain. Deficiency or lack of essential fatty acids (EFAs) in mammals 
causes physiological disorders and is incompatible with life. 
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Figure 7: Myelin membrane composed of asymmetrically distributed phospholipids, and major 
myelin proteins. Zoomed box: depicting a phospholipid; phosphatidylcholine with its saturated and 
unsaturated hydrophobic fatty acid tails and the hydrophilic choline polar head group (Adopted and 
modified from Uschkureit, 2000). 
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1.5.2 Classification of fatty acids and the polyunsaturated fatty acids (PUFAs) synthesis 
cascade 
 
Fatty acids are broadly classified into saturated and unsaturated fatty acids based on the number 
of carbon-carbon double bonds. Saturated fatty acids have no carbon-carbon double bonds, e.g. 
palmitic acid (16:0) and stearic acid (18:0). They are mostly involved in energy storage in the 
form of triglycerides in adipose tissue and are also major structural components in membrane 
phospholipids. Unsaturated fatty acids are classified into monounsaturated fatty acids (MUFAs) 
and polyunsaturated fatty acids (PUFAs). MUFAs contain only a single carbon-carbon double 
bond, e.g., oleic acid (18:1, n-9). PUFAs are further classified into omega-9, omega-6, and 
omega-3-fatty acids (Figure 8) and contain more than one carbon-carbon double bond. PUFAs 
are the important structural constituents of membrane phospholipids; their carbon-carbon double 
bonds introduce kinks in the membrane phospholipids. The degree of double bonds or 
unsaturation in the phospholipid fatty acid chains may increase membrane fluidity and decrease 
membrane melting point and transition temperature. PUFAs such as arachidonic acid (AA), 
docosahexanoic acid (DHA), are also involved in cell signaling and are precursors for variety of 
metabolic processes. According to the omega (ω/n) classification system, the carbon-carbon 
double bond numbering starts from the methyl carbon terminal.  
 
  
 
Figure 8: Fatty acid classification with their common and systematic names and abbreviations. 
PUFAs classification into omega-9, omega-6 and omega-3, and some fatty acids structures were depicted.  
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Polyunsaturated fatty acid biosynthesis   
 
In mammals, the majority of PUFAs are acquired from diet and by transforming from their 
precursors essential fatty acids (EFAs) such as linoleic acid (18:2, n-6) and alpha-linolenic acid 
(18:3, n-3) endogenously via specific fatty acid synthases, elongases, and desaturases.  
In mammals, delta-desaturases such as delta-9, delta-5, and delta-6 introduce double bonds at 
defined positions in respective fatty acids. Delta-9 desaturases, also called stearoyl-CoA 
desaturase-1 (SCD), introduce the double bond at the 9, 10 position from the carboxylic terminal 
in 18:0 fatty acid (Figure 9) thus generating 18:1 (n-9) monounsaturated fatty acid. Four SCD 
isoforms have been identified in mouse and they are tissue-specific. The SCD1 isoform is 
expressed in liver whereas SCD2 is brain specific, and SCD3 and SCD4 isoforms are skin and 
heart specific, respectively. In the PUFA synthesizing cascade, elongase is involved in extending 
the fatty acid chain.  
PUFAs (n-3 and n-6) are synthesized by desaturation from their respective precursor fatty acids 
in the ER membrane by ER membrane-bound desaturases i.e., delta-5 desaturase also called as 
Fads1, and delta-6 desaturase also called as Fads2. Fads1 introduces at position 5 the cis double 
bond in their respective precursor fatty acyl chains, Fads2 at position 6 of EFAs in the initial and 
further steps of the PUFA biosynthetic pathway (Figure 9). Lack of fads2 enzyme disrupts PUFA 
biosynthesis, thereby abolishing synthesis of endogenous the major PUFAs such as AA (20:4 n-
6), EPA (20:5, n-3), and DHA (22:6, n-3), along with very long chain-PUFAs (Stoffel et al., 
2008; Stroud et al., 2009). 
                              
Figure 9: The cascade of PUFA biosynthesis by desaturases and elongases in mammals. 
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1.5.3 PUFAs in the CNS 
 
PUFAs and very long chain-PUFAs (VL-PUFAs) are the major components in phospholipids of 
the myelin membrane in the CNS. Among the PUFAs, AA and DHA are the major constituents 
of the CNS brain and in retinal phospholipids in contrast to other cell membranes. It is known 
that AA and DHA are highly conserved and are critical for normal physiological functions in the 
brain and retina (Carrie et al., 2000a). AA and DHA are also precursors of eicosanoids and 
docosanoids, respectively, and also carry out a myriad of pharmacological functions. 
Deficiency of PUFAs may disrupt membrane bilayer conformation, cell polarity and tight 
junctions, which might in turn disrupt respective physiological functions. This has been shown in 
Sertoli cell polarity and in blood testis-barrier, and in granulosa cells of ovarian follicles (Stoffel 
et al., 2008).   
The supplementation of omega-3 and omega-6 PUFAs for brain development, especially in early 
myelin developmental stages, is an active research area in nutritional and brain physiology 
(Yehuda et al., 2002). Miller et al., 1984 demonstrated that a lack of essential fatty acids (EFAs) 
results in a decrease of total myelin protein content to 25%, lipid phosphorous content to 22%, 
brain weight to 7% and a reduction in body weight up to 40%. PUFAs play an important role in 
myelinogensis by influencing myelin gene expression levels (Clarke, 2001). Eicosapentaenoic 
acid (EPA) supplementation to glial cells in vitro up-regulated PLP gene expression levels via 
cAMP-mediated pathways (Salvati et al., 2004), whereas under DHA supplementation PLP gene 
expression is up-regulated via retinoid X receptor signaling pathway (Jang et al., 2004).  In vivo, 
injecting DHA and EPA into rat brain stimulated several myelin proteins such as PLP, MBP, 
MOG and CNP, via down-regulating CREB (cAMP-response element-binding) activity due to 
decreased levels of CREB phosphorylation (Salvati et al., 2008). In clinical studies PUFAs 
supplementation has been promising in remyelination, especially in multiple sclerosis (MS) with 
demyelinating disorder. PUFAs are also used in minimizing neurotoxin levels in schizophrenia. 
In mammals, perturbed behavioral physiology such as impaired cognitive ability and motor 
coordination has been observed in EFA deficient conditions (Vinot et al., 2011; Chengwei He et 
al., 2009). 
Retinal photoreceptor rods and cones outer segments (OS) consist of thousands of vertically 
staked membrane disks that are made up of lipoprotein bilayers enriched with DHA and AA 
(Bazan et al., 1993). Electroretinography (ERG) is used to assess retinal photoreceptor function 
and retinal photo-transduction cascade which is triggered in response to light (Weisinger et al., 
1996a). ERG output is the direct measurement of the visual function of the retina in the presence 
of light. LC-PUFA deficiency may affect the rod outer membrane and RPE membrane and thus 
may impair normal visual functions (Jeffrey et al., 2001). 
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1.5.4 Retinal morphology 
 
In vertebrate embryonic development, the retina and optic nerve originate as an outgrowth of the 
developing brain. The vital role of the retina is in the conversion of light signals into nerve 
impulses that are passed along the optic nerve to different visual centers of brain. Outer segments 
of retinal photoreceptors and retinal synapses are highly enriched in PUFAs, specifically DHA. 
The retinal pigment epithelium (RPE) is involved in nutrient transport and removal of waste 
products from photoreceptors by the apical microvilli. The basal surface of the RPE interacts 
with underlying Bruch membrane (Figure 10). RPE is separated from the choriocapillaris (CC) 
by Bruch membrane (Figure 10). The outer segments (OS) are made up of sensory cilia and a 
series of membrane stacks composed of 60% of DHA, which are important in light conduction. 
DHA depletion may result in retinal degeneration and functional impairments. 
 
          
Figure 10: Morphology of the retinal layers (Human). Right upper diagram depicts the layers of the 
retina: CC, choriocapillaris, BM, Bruch’s membrane; RPE, retinal pigment epithelium; ap, apical 
processes or RPE apical microvilli; os, outer segments; C, cones, R, rods; M, Müller cells. Right lower 
image: electron micrograph of human retinal RPE region (adapted and modified from Web vision-retina) 
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1.5.5 Fads2 knock-out mouse (PUFAs deficient mouse model)  
 
The fads2 (Delta6) null mouse mutant has been generated in our lab (Stoffel et al., 2008) to 
investigate the functional significance of PUFAs deficiency without depleting their precursor 
EFAs (LA and ALA). The fads2 null mouse lack the synthesis of all PUFAs including AA and 
DHA along with their derivatives such as eicosanoids and LC-PUFA (Stoffel et al., 2008, Stroud 
et al., 2009). Since DHA and AA are the major representatives among PUFAs in the brain and 
retina, lack of endogenous PUFAs biosynthesis especially AA and DHA in the fads2 null mouse 
mutant enables us to investigate the significance of PUFAs in membrane structure and function 
focusing on the CNS i.e., brain and retina. 
The generation of gene targeted mouse mutants (transgenic mice), in which key enzymes of lipid 
biosynthesis have been deleted are central to the key strategy to unravel the role of specific lipid 
functions. These models are similar to the mouse models in which key protein structures of CNS 
have been deleted.  
 
 
1.6 Transgenic mouse models 
 
A very important method for analyzing gene function, from its role in normal development to 
pathology, is possible by generating gene manipulated mouse models, in which a specific gene of 
interest is deleted, modified or over-expressed. Genetically engineered mouse mutants can be 
obtained by several ways, such as by gene targeting (Capecchi et al., 1994) in which the 
endogenous copy of a gene is partly or completely deleted by homologous recombination, or by 
pronuclear injection technique (Gordon and Ruddle, 1983) where a gene can be over-expressed 
at random loci in the genome. 
 
 
1.6.1 Gene targeting  
 
The technique of gene targeting involves the mutation of a specific gene locus by the 
homologous recombination in embryonic stem cells. It is most often employed for generating 
gene knock-out or knock-in mutants. In the gene knock-out approach, specific gene function is 
usually eliminated by deleting partly or completely the endogenous gene by homologous 
recombination, whereas in a gene knock-in approach, instead of eliminating gene function the 
gene is manipulated as desired, e.g., by introducing point mutations in specific loci. 
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In the gene targeting technique, initially a gene-targeting construct with the desired 
modifications such as point mutations, partial gene deletions, insertion of fluorescent gene 
markers etc., is engineered. This is then cloned into a gene targeting vector and further 
transfected into pluripotent ES cells. The mutated homologous gene fragment then recombines 
with the endogenous gene counterpart in the ES cells (Thomas and Capecchi, 1986). Increased 
length of the exogenous targeting homologous arms will increase the frequency of homologous 
recombination with the endogenous locus (Hasty et al., 1991b). The targeting vector also 
contains one or more selection markers such as a neomycin resistance gene and a thymidine 
kinase gene from herpes simplex virus (HSV-TK). Positive or negative selection markers allow 
for screening of homologously recombined clones from a pool of clones (Mansour et al., 1988). 
Successfully homologously recombined positive ES clones will be verified by PCR and Southern 
blot hybridization. Positive ES clones are then injected into mouse embryos at the blastocyst 
stage (Bradley et al., 1984) and re-implanted in to pseudo-pregnant foster mice. Thus obtained 
chimeric progeny are verified by PCR and DNA sequencing. The verified chimeras can be 
further bred to generate germ line chimeric heterozygotes and further to homozygous mutants. 
 
 
1.6.2 Pronuclear Microinjection  
 
The pronuclear micro-injection technique is fast and robust for generating transgenic mouse 
mutants to investigate gene function in vivo. An exogenous gene or cDNA from the appropriate 
gene, termed transgene, is introduced into the pronucleus of fertilized murine eggs by 
microinjection. The transgene is a DNA fragment usually containing a tissue-specific enhancer, 
promoter, and the gene-of- interest (gene or protein coding CDNA). In this technique, multiple 
transgene copies are stably integrated into the mouse genome at random loci. Pronuclei injection 
technique can be used to investigate gene gain-of-function (Babinet, 2000), and gene localization 
by tagging or fusing gene of interest with the appropriate reporter gene such as EGFP or E. coli 
beta-galactosidase. The transgene can also micro-injected into the fertilized eggs from a specific 
genetic background such as a null-mutant. The main disadvantage of the transgenic technique is 
the position effect, i.e., the pronuclear injected transgene integrates randomly and therefore may 
disturb the function of other genes. Hence large numbers of founder mice have to be analyzed to 
assess the true function of the injected transgene.  
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1.7 Site-directed mutagenesis 
 
The site-directed mutagenesis (SDM) technique is used to introduce mutations (point or 
multiple), insertions and deletions at desired positions in a DNA fragment, by using synthetic 
oligonucleotides (Itakura et al., 1984; Carter, 1986). In SDM, the DNA sequence that has to be 
manipulated is employed as a template in the PCR reaction with mismatched nucleotide 
containing primers, and these primers are then extended on the template synthesizing new DNA 
fragments incorporating the mutations or mismatches. Among various methods of PCR-based 
mutagenesis, basic strategies employed within this thesis work are conventional PCR 
mutagenesis, which introduces mutations towards the 5’end and 3’ ends of the desired template 
DNA fragment, and overlap-extension PCR, which introduces mutations at more than one 
desired location within the target DNA template fragment.  
In overlap-extension PCR, multiple mutations are introduced in a single PCR reaction by 
employing more than one set of primers containing nucleotide mismatches (mutations). It can 
also be employed by combining two individual DNA fragments at their terminal overlapping 
sequence. 
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2 Aim of the thesis 
 
 
Proteolipid protein (PLP) is a major structural element in the ordered myelin architecture and is 
an essential component for the maintenance of myelin sheath in CNS. PLP and its isoform Dm20 
contain 14 Cys and 12 Cys residues respectively; in which six Cys residues are involved in post-
translational thio-acylation modification and four Cys residues in two disulfide bridge formation 
that are localized in extra cellular loop-II. These Cys-residues may be critical for maintaining the 
topological structure of PLP in the membrane. It is well known that some point mutations of PLP 
effects its conformational changes and perturbs the intracellular trafficking of PLP, leading to the 
apoptosis of oligodendrocytes there by resulting in severe forms of dysmyelinating CNS diseases 
such as PMD and SPG2. 
The primary aim of the present study is to identify the function of Cys residues (Cys-mut-PLP 
and Cys-mut-Dm20 proteins) in PLP and its isoform Dm20, as structural elements and their role 
in intracellular trafficking under in vitro and in vivo conditions. As a part of this, a transgenic 
mutant mouse expressing a mutant form of PLP (Cys-mut-PLP) under the control of promoters 
of early neuronal or glial cell lineage markers (MBP promoter and Nestin enhancer) on the PLP 
null background will be generated. Simultaneously, in order to understand the significance of the 
two disulfide bridges formed by the four Cys residues in PLP and Dm20, a knock-in mutant 
mouse lacking the disulfide bridges of endogenous PLP and Dm20 has to be generated by 
homologous recombination. As the first step, a targeting construct will be generated containing 
the PLP gene sequence with mutated four Cys residues that are involved in the formation of two 
disulfide bridges. 
     
The integral membrane protein PLP, and phospholipid’s polyunsaturated fatty acids (PUFAs), 
play significant structural and functional roles in the CNS myelin sheath. The plp-/- knock-out 
mouse generated previously in our laboratory revealed that the lack of PLP resulted in disruption 
of CNS myelin membrane compaction and long term axonal maintenance but did not show any 
dysmyelination, hypomyelination or other severe neurological disorders. The fads2-/- knock-out 
mouse that was generated in our laboratory has completely abolished endogenous in vivo PUFA 
synthesis, and even more close observation revealed disrupted gap-junctions in Sertoli cell 
polarity and blood-testis barrier in addition to the gap junction network between granulosa cells 
of ovarian follicles. Hence, the generation of a plp-/-fads2-/- double knock-out mouse would 
reveal the significant functional and structural roles of two pivotal structures PLP and PUFA in 
the organization of myelin membrane of CNS.  
The second aim of this dissertation is to generate a plp-/-fads2-/- double knock-out mouse and to 
characterize the ultra structural phenotype of myelin membrane using biochemical, cellular, and 
behavioral studies. Since the retina is a part of the CNS and its photoreceptor outer segment 
membranes are primarily composed of PUFA such as DHA, its structural features along with its 
functions will also be investigated. 
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3 Results 
 
 
3.1 Construction of mutant cDNA pool of PLP and Dm20 
 
 
3.1.1 Site-directed mutagenesis (SDM) and Overlap extension PCR  
 
In order to study the role of PLP and Dm20 Cys residues in intracellular and plasma membrane 
trafficking under in vitro and in vivo conditions, PLP and Dm20 cDNA constructs containing 
Cys point mutations at desired positions were generated (Table 3).  
Total mRNA isolated from adult C57BL/6 mouse brain was used as a template to derive PLP and 
Dm20 cDNA fragments by RT-PCR. Site-directed mutagenesis (SDM) and overlap extension 
PCR techniques were performed as follows: two pairs of point mutated primers were used to 
generate two 5’ and 3’ incomplete overlapping cDNA fragments in two separate PCR reactions. 
Subsequently, these two overlapping cDNA fragments were annealed, extended, and amplified to 
generate full length cDNA fragments with appropriate Cys mutations. Using this method, Cys 
codons of PLP and Dm20 cDNA were mutated to Ser codons at the desired positions. The 
lengths of the cDNA fragments were confirmed by agarose gel electrophoresis and the mutations 
introduced were confirmed by DNA sequencing (Figure 11 and 12). 
Similarly, a total of ten PLP cDNA fragments and nine Dm20 cDNA fragments with Cys codons 
at defined positions mutated to Ser codons were generated. These amplified cDNA fragments 
were cloned into the PCR2.1 vector (Invitrogen). Thus generated cDNA inserts were used for 
further cloning steps to generate final vectors for the study of their in vivo intracellular targeting 
properties. cDNA mutations are illustrated in the figure 11 B. 
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Figure 11: A) Agarose gel electrophoresis of cDNAs of PLP (825bp) and Dm20 (723bp) and DNA 
Marker (Biolabs). B) PLP and Dm20 transmembrane structure. The intracellular hydrophilic loop of 
amino acids 116 to 150 are specific to PLP (violet dotted line) but are absent in Dm20. Transmembrane 
structure: four hydrophobic membrane spanning domains (shaded bars) are connected by five hydrophilic 
domains (blue lines). Cytosolic domains encoded by partial or complete exons I, II, III, IV, VII, and 
extracellular domains by partial exons II, IV, V and VI were represented. Positions of Cys residues 
mutated to Ser residues were represented. 
 
 
No
. 
Name of 
the cDNA 
Construct 
PLP/ 
Dm20 
Mutated Cys codons position, deleted 
S-acylation or disulfide bridge Cys-
codons position 
Mutate
d Exon 
Average 
Protein 
Hydrophobi
c value 
1 Wild-type 
(WT) 
PLP Nil  0 0,550181 
2 -ca PLP 5,6,9   II  
3 -C34 PLP 5,6,9,24,32,34  II  
4 -C108 PLP 5,6,9,24,32,34,108  II,III  
5 -C140 PLP 5,6,9,24,32,34,108,138,140  II,III  
6 -C168 PLP 5,6,9,24,32,34,108,138,140,168  II,III  
7 -C183 PLP 5,6,9,24,32,34,108,138,140,168,183  
(removed first proximal disulfide 
bridge) 
II,III,IV  
8 -C200 PLP 5,6,9,24,32,34,108,138,140,168,183,200  
(removed two disulfide bridges) 
II,III,IV  
9 -C219 PLP 5,6,9,24,32,34,108,138,140,168,183,200 II,III,IV,  
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,219 
 
V 
10 Mut-PLP 
(Cys-less 
PLP) 
PLP All Cys residues mutated to Ser resides 
5,6,9,24,32,34,108,138,140,168,183,200
,219,227 
 
II,III,IV,
V 
0,38339 
11 Wild-type Dm20 Nil 0 0,780579 
12 -ca Dm20 5,6,9  II  
13 -C34 Dm20 5,6,9,24,32,34  II,III  
14 -C108 Dm20 5,6,9,24,32,34,108  II,III  
15 -C168 Dm20 5,6,9,24,32,34,108,138,140,168  II,III,IV  
16 -C183 Dm20 5,6,9,24,32,34,108,138,140,168,183 
( Removed first proximal disulfide 
bridge) 
II,III,IV  
17 -C200 Dm20 5,6,9,24,32,34,108,138,140,168,183,200 
(Removed two disulfide bridges) 
II,III,IV  
18 -C219 Dm20 5,6,9,24,32,34,108,138,140,168,183,200
,219  
II,III,IV  
19 Mut-
Dm20 
(Cys-less 
Dm20) 
Dm20 All Cys residues mutated to Ser residues  
5,6,9,24,32,34,108,138,140,168,183,200
,219,227 
 
II,III,IV,
V 
0,616942 
 
Table 3: Generated constructs of PLP and Dm20 cDNA with point mutated Cys codons. 
Nomenclature representing positions of the mutated Cys residues and their corresponding exons are listed. 
In silico average protein hydrophobicity values (Section 3.2) are indicated. 
Bold, underlined and italicized numbers indicate mutated Cys positions with deleted S-acylation sites. 
Bold, underlined and italicized numbers indicate Cys positions involved in of Disulfide bridges. 
 
 
3.1.2 DNA sequencing  
 
Cys codons mutated to Ser codons in cDNA fragments generated (Section 3.1, Table 3) were 
confirmed by DNA sequencing. In Mut-PLP and Mut-Dm20 all the Cys codons were mutated to 
Ser codons. 
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Figure 12: DNA sequencing results of Mut-PLP/Dm20. All 14 Cys codons that were interchanged to 
Ser codons were verified. 
 
 
3.2 In silico Kyte-Doolittle hydropathy plots 
 
Trafficking of PLP to the plasma membrane depends on factors such as hydrophobic properties 
and protein lipidation. The shift in hydrophobicity may affect PLP/Dm20 sorting and trafficking 
to the membrane (Kraemer-Albers et al., 2006). 
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In silico Kyte-Doolittle hydropathy plots (Kyte and Doolittle 1982) based on amino acid 
sequences of WT-PLP, Mut-PLP (Cys substituted to Ser PLP), WT-Dm20, and Mut-Dm20 (Cys 
substituted Ser Dm20) were generated. The DNASTAR Protean program with a minimizing 
parameter of window 11, as suggested for PLP/Dm20 (Dhaunchak et al, 2011) was used. Kyte-
Doolittle hydropathy plots can indicate potential transmembrane protein structure and 
hydrophilic surface regions (Kyte and Doolittle, 1982). 
WT-PLP, Mut-PLP, WT-Dm20 and Mut-Dm20 hydropathy plots indicated four hydrophobic 
transmembrane domains (TM). WT-PLP and Mut-PLP plots also indicated an additional 
hydrophilic domain of PLP specific (Figure 13 A.I, blue box) in comparison to WT/Mut-Dm20 
plots, were in agreement with the biochemical topology studies of PLP  by Weimbs and Stoffel, 
1992. 
 Compared with the WT-PLP plot, the Mut-PLP plot showed a partial extended hydrophilic 
domain into hydrophilic space i.e., in between TM II and III (Figure 13 A.II, red box) which 
might corresponds to the in vivo PLP topology intracellular PLP specific hydrophilic loop. The 
Mut-Dm20 plot also showed an extended hydrophilic domain into the hydrophilic space (Figure 
13 B.II, red box) but not with considerable difference from WT-Dm20. In silico amino acid 
hydropathy index values (Figure 13 C) were obtained from SOSUI program (Mitaku et al., 2002) 
which predicted reduced hydropathy index values for mutated forms in comparison to the WT 
forms of PLP and Dm20 (Figure 13 C).  
Thus in silico prediction of hydrophobic properties i.e. based on hydropathy plots or 
hydrophilic/hydrophobic structural orientation (Figure 13 A and B), and amino acid hydropathy 
index (Figure 13 C) suggest that under in vivo conditions there might be a considerable decrease 
of hydrophobicity from WT to mutated forms of PLP and Dm20. Moreover, in Mut-PLP there 
may be a partial but considerable conformational disturbance within the hydrophilic domain 
compared to WT-PLP. This might alter normal plasma membrane trafficking of Mut-PLP and 
Mut-Dm20 compared to WT forms in vivo.  
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Figure 13: In silico Kyte and Doolitle hydrophobicity/hydrophilicity plots of WT-PLP/Dm20, Mut-
PLP/Dm20: In the plot, positive values indicate predicted hydrophilic structural orientation whereas 
negative values indicate predicted hydrophobic structural orientation. All plots, including WT and 
mutated forms, predict four transmembrane hydrophobic domains with additional features. Plots were 
generated from the DNASTAR, Protean software with a minimizing window of 11, with amino acid 
sequence as input. 
A. I) The WT-PLP plot depicting four hydrophobic domains (TM-I, II, III and IV) in negative values, and 
also a hydrophilic PLP loop in positive values (blue box in figure A.I) is in agreement to the in vivo PLP 
topology II) In the Mut-PLP plot, the hydrophilic PLP loop specific region is partial disturbed and 
considerably extends into hydrophilic space (red box figure A, II) in comparison to that of PLP specific 
region of WT-PLP plot (Figure A, I) demonstrating that Mut-PLP is less hydrophobic and with a partial 
structural disturbance (red box) in comparison to WT-PLP. 
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B. I) WT-Dm20 plot; Line - indicates an extension of hydrophobic stretch of TM-III that is absent in WT-
PLP plot. II) Mut-Dm20 showing an extended loop after TM-III in hydrophilic space (Red Box) in 
comparison with WT-Dm20 plot which predicts that Mut-DM20 is partially altered with no considerable 
differences. 
C. Hydropathy index values obtained from SOSUI program. Hydrophobicity values obtained for 
individual proteins is depicted; WT-Dm20 > Mut-Dm20 > WT-PLP > Mut-PLP.  
 
 
3.3 EGFP fused WT-PLP, Mut-PLP, and Mut-Dm20; Intracellular trafficking 
 
EGFP fused WT-PLP, Mut-PLP (Cys-less PLP), and Mut-Dm20 (Cys-less Dm20) cloning and 
their intracellular trafficking were studied in vitro in non-glial cell line (i.e., COS-7 cells) and in 
vivo in glial cells (i.e., primary oligodendrocytes) as follows.  
 
 
3.3.1 Cloning and validation of WT-PLP-EGFP, Mut-PLP-EGFP and Mut-Dm20-EGFP 
 
WT-PLP, Mut-PLP and Mut-Dm20 cDNA constructs were obtained from the previously 
generated cDNA pool (Table 3). These cDNA fragments were used as templates for site-directed 
mutagenesis (SDM). By SDM, an XhoI restriction site was introduced at the 5’ end and a 
mutated stop codon along with PstI restriction site was introduced at the 3’end of PLP/Dm20 
cDNA. Thus prepared WT-PLP and Mut-PLP and Mut-Dm20 cDNA fragments were cloned into 
the EGFP.N2 expression plasmid (Clonetech) using XhoI and PstI restriction sites. Appropriate 
directional insertion and Cys mutations were confirmed by restriction analysis and by DNA 
sequencing.  
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Figure 14: Schematic representation of A. WT-PLP-EGFP, B. Mut-PLP-EGFP and C. Mut-Dm20-
EGFP constructs, and their corresponding protein structures including Cys mutations. N terminal 
CMV promoter, respective cDNA with eliminated stop codon was fused to N terminal EGFP in EGFP.N2 
expression plasmid.  
 
3.3.2 Mut-PLP-EGFP and Mut-Dm20-EGFP compared to WT-PLP-EGFP trafficking in 
COS-7 cells 
 
Intracellular trafficking and plasma membrane targeting of the above cloned constructs WT-
PLP-EGFP, Mut-PLP-EGFP, and Mut-Dm20-EGFP were studied in vitro in COS-7 cells.  
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Transfection and immunocytostainings were carried out as described in methods (Section 6.1.9). 
WT-PLP-EGFP transfected COS-7 cells immunocytostaining revealed that WT-PLP-EGFP 
(green) co-localizes in the plasma membrane projections (filopodia) and at the plasma membrane 
with anti-PLP (Cy3-red) staining (Figure 15 A-D and Inset, Figure 16.I A and D (Inset)). These 
results were consistent with previous results (Koizume et al., 2006). Intriguingly, 
immunocytostaining of COS-7 cells transfected with Mut-PLP-EGFP and Mut-Dm20-EGFP 
individually revealed neither Mut-PLP-EGFP (green), Mut-Dm20-EGFP (green) or anti-PLP 
(CY3-red) staining was detected in the filopodia, at plasma membrane or at the cell surface 
(Figure 15 E-L and Inset). 
Furthermore, the WT-PLP-EGFP, Mut-PLP-EGFP and Mut-Dm20-EGFP (green) were co-
localized with the K58 (Golgi marker, Cy3-red) and BiP (ER marker, Cy3-red), (Figure 16.I E-L, 
Figure 16.II, arrows).  
 
Overlay
Mut
Dm20 
tagged 
with 
EGFP
Dapi staining PLP-Cy3 PLP/Dm20-EGFP 
WT
PLP 
tagged 
with 
EGFP
Mut
PLP 
tagged 
with 
EGFP
A B C D
E F G H
I J K L
 
Figure 15: Localization of WT-PLP-EGFP, Mut-PLP-EGFP, and Mut-Dm20-EGFP fusion proteins 
in COS-7 cells. Immunostaining was performed with anti-PLP (1:200) and Cy3 conjugated secondary 
antibody (Jackson anti-rabbit-Cy3, 1:800) along with DAPI (for nuclei). Overlay = PLP/Dm20-EGFP 
(green), anti-PLP-Cy3 (red) and Dapi (blue).  
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Figure 16: Localization of WT-PLP-EGFP, Mut-PLP-EGFP, and Mut-Dm20-EGFP fusion proteins 
in COS-7 cells.  
The staining was performed with Golgi apparatus and endoplasmic reticulum (ER) specific markers: 
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I) Staining with K58 (1:100, Sigma) and Cy3 conjugated secondary antibody (Jackson anti-rabbit-Cy3, 
1:800) and DAPI. PLP/Dm20-EGFP (green), anti-K58/Cy3 (red) and Dapi (blue). Overlay = EGFP 
(green) + anti-K58/Cy3 (red) + Dapi (blue).  
II) Staining with anti-BiP (1:200, Biomol) and Cy3 conjugated secondary antibody (Jackson anti-rabbit-
Cy3, 1:800) and DAPI (blue). PLP/Dm20-EGFP (green), anti-BiP-Cy3 (red) and Dapi (blue). Overlay = 
EGFP (green) + anti-K58/Cy3 (red) + Dapi (blue). 
 
 
3.3.3 WT-PLP-EGFP and Mut-PLP-EGFP trafficking in PLP null oligodendrocytes 
 
To understand the intracellular trafficking of WT-PLP-EGFP and Mut-PLP-EGFP under in vivo 
conditions, we employed primary cultures of oligodendrocytes derived from neonatal PLP-/- 
mice brain. Oligodendrocytes derived from plp-/- mice, lacks endogenous WT-PLP production 
which has been genetically deleted, and are perfect tissue culture models, which mimic glial 
lineage.  
 
 
3.3.3.1 Isolation and transfection of PLP-null murine oligodendrocytes 
 
Progenitor oligodendrocytes or oligodendrocytes were isolated from neonatal PLP-/- mice brain 
during their early myelination phase p7-p10 (7-10 days old) using Macs-columns (Miltenyi) for 
oligodendrocyte purification (Miltenyi; Cizkova et al., 2009). Oligodendendrocytes were further 
tested with various oligodendrocyte specific markers for determining the oligodendrocyte 
quality. Thus derived primary oligodendrocyte cultures were transiently transfected with WT-
PLP-EGFP and Mut-PLP-EGFP DNA constructs. Immunocytostainings were carried out 24-46 
hours after transfection. 
 
 
3.3.3.2 WT-PLP-EGFP and Mut-PLP-EGFP membrane targeting in oligodendrocytes  
 
The WT-PLP-EGFP transfected oligodendrocytes revealed that WT-PLP-EGFP (green) was 
observed in the filopodia and at plasma membrane, which was also confirmed by anti-PLP (cy3-
red) immunostaining (Figure 17). On the other hand, Mut-PLP-EGFP transfected 
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oligodendrocytes revealed that Mut-PLP-EGFP fluorescence (green) was detected only in the 
cytoplasm and not in filopodia or at the plasma membrane, which was also confirmed by the 
anti-PLP (Cy3-red) immunostaining (Figure 18). 
Although WT and mutant forms of PLP/Dm20 were extensively expressed in the cytoplasm, they 
show differential sorting, trafficking and integration into the plasma membrane. WT-PLP-EGFP 
is sorted and integrated into the plasma membrane but Mut-PLP-EGFP failed to be recruited to 
the plasma membrane. These in vivo or native cell type system results are consistent with the 
plasma membrane trafficking results observed under in vitro conditions in COS-7 cells (Section 
3.3.2). 
 
                             
     
Figure 17: Localization of WT-PLP-EGFP in PLP null oligodendrocytes. WT-PLP-EGFP transfected 
oligodendrocytes immunostained with anti-PLP (1:200) and a Cy3 conjugated secondary antibody 
(Jackson anti-rabbit, 1:800) and Dapi; WT-PLP-EGFP (green), anti-PLP (Cy3/red), and nucleus (blue).  
Overlay= WT-PLP-EGFP (green) + anti-PLP (Cy3/red), + Dapi (blue). 20µm scale 
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Figure 18: Localization of Mut-PLP-EGFP in PLP null oligodendrocytes. Mut-PLP-EGFP 
transfected oligodendrocytes immunostained with anti-PLP (1:200) and Cy3 conjugated secondary 
antibody (Jackson anti-rabbit, 1:800) and Dapi; Mut-PLP-EGFP auto-fluorescence (green), anti-PLP 
(Cy3/red), nucleus (blue). Overlay=Mut-PLP-EGFP (green) +anti-PLP (Cy3/red) +dapi(blue). 20µm scale 
 
3.4 Mut-PLP expression under the control of Nestin-enhancer; generation of a transgenic 
mutant 
 
 
3.4.1 Validation of Nestin enhancer function in OLN93 cells 
 
We validated the Nestin enhancer gene element (human nestin gene II-Intron sequence (Lothian 
and Lendahl, 1997) as a controlling element for regulating the Mut-PLP (Cys-mut PLP) 
expression, as follows. 
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Cloning: Nestin enhancer sequence (1.8 kb) with a HSV-TK promoter was obtained from 
Lothian and Lendahl, and cloned into the pBSKII(+/–) vector. The Mut-PLP cDNA fragment 
(listed in Section 3.1, Table 3) and a poly (A) tail (Clontech) was engineered at the 3’ end of the 
HSV-TK promoter. Orientation of the individually cloned fragments was confirmed by 
restriction digestion and by DNA sequencing. 
             
Figure 19: NesMut-PLP construct. From 5’ to 3’ direction: Nestin enhancer, tk promoter, Mut-PLP 
cDNA and polyA tail, cloned into the pBSKII(+/–) vector.  
 
Over-expression and semi-quantification of Mut-PLP mRNA over-expression in OLN93 
 
The Nestin-Mut-PLP construct was transfected into OLN93 cells. Expression levels of PLP and 
Dm20 mRNAs were then quantified with cDNA specific primers.  
Total mRNA was isolated from NesMut-PLP transfected OLN93 cell lines (clones 3 and 4) and 
non-transfected OLN93 cell lines. Isolated mRNA was reverse transcribed with universal 
primers to generate total cDNA, and PLP and Dm20 cDNA specific primers were used for qRT-
PCR. HGPRT cRNA primers were used as a loading control. In contrast to non-transfected 
OLN93 cells, the NesMut-PLP transfected OLN93 cell clones A and B showed two fold higher 
expression of PLP mRNA. The Dm20+PLP mRNA levels in clone A and B revealed constant 
Dm20 mRNA levels (Figure 20). This data suggests that the nestin enhancer can drive Mut-PLP 
over-expression in OLN93 cells. 
          
     Figure 20: Semi-quantitative RT-PCR: WT (untransfected OLN93 cells), and clone A and B of 
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NesMutPLP transfected OLN93 cells. Densitometric data from RT-PCR analysis. Data represented from 
three independent experiments (mean± SEM).  
 
 
3.4.2 Nh/MBPMut-PLP Transgenic mice generation 
 
Transgenic mice with Nestin enhancer and Mbp promoter driven Mut-PLP has been generated to 
address the points of 1) Nestin enhancer regulation in early glial precursors i.e., O4 and 
oligodendrocytes 2) expression and control of MBP promoter plus Nestin enhancer on Mut-PLP 
3) the impact of the loss of post-translational S-acylation of PLP on its functional activity in 
intracellular trafficking, myelinogenesis and in myelin compaction and maintenance, and 5) the 
role of Mut-PLP in Pelizaeus–Merzbacher disease. 
Since it has been shown previously that MBP expression is crucial and specific for myelination 
and it is expressed in early and mature glial cells we employed the MBP promoter, which has 
been well characterized in our laboratory (Stefan Meinzinger, 2004), together with the Nestin 
enhancer in cloning of the transgene construct.  
In the transgene, the enhanced green fluorescent protein sequence together with IRES (internal 
ribosome entry site) sequence was engineered to the 3’ end of the Mut-PLP cDNA. 
 
 
3.4.2 Trans-gene cloning and pronuclear injection 
 
a. Trans-gene cloning  
 
The HSV-TK promoter of NesMut-PLP construct (Figure 19) was replaced with the 1.2 kb MBP 
promoter sequence obtained from Meinzinger, 2004. A 1.8kb EGFP with poly(A) tail DNA 
(Clontech) was then cloned into the XhoI sites to the 3’ end of Mut-PLP. Orientation of the 
individual fragments was confirmed by restriction digestion and DNA sequencing. The generated 
Nh/MBPMut-PLP transgene construct (Figure 21) was used for pronuclear injection.  
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Figure 21: Pronuclear injection (PNI) construct: A. Nh/MBPMut-PLP; 5’ to 3’ direction cloned 
fragments of Nestin enhancer, MBP promoter, Mut-PLP, IRES and EGFP with a Poly(A) tail. B. Agarose 
gel depicting the trans-gene construct of 5.1 kb. Lane I: non-linearized construct (as a control), Lane II: 
linearized trans-gene construct. 
 
 
b. Pronuclear injection  
 
A transgenic mouse has been generated by pronuclear injection. The Nh/MBPMut-PLP 
transgene was injected into the pronuclei of oocytes derived from PLP null mutant females. 
The ultra purified Nh/MBPMut-PLP transgene DNA fragment was injected into the pronuclei of 
oocytes or fertilized eggs of plp-/- female mice. To obtain fertilized eggs (oocytes), plp-/- 
transgenic female mice were super ovulated and mated with plp-/- male mice. From 5 super-
ovulated plp-/-female mice, 50-60 fertilized eggs were isolated for micro injection of 
Nh/MBPMut-PLP transgene construct into their male pronuclei.  
 
Pronuclear injection derived mice 
S.No Total No. of plp-/- 
oocytes injected with 
transgene construct 
 
No. of litters 
born 
No. of litters 
containing transgene 
construct 
Founder/Transgene 
mice obtained 
1 270 6 0 - 
 
Table 4: Summary of the performed pronuclear injection experiments. 
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3.5 Generation of knock-in mouse mutant of PLP/Dm20 devoid of di-sulfide bridges 
 
Gene-targeted mouse models are approved systems to investigate neurological disorders at the 
molecular level in vivo. In order to study the functional consequences of PLP devoid of the two 
disulfide bridges (Cys183 with Cys 227 and Cys200 with Cys 219) in vivo, a PLP knock-in mouse 
mutant is being generated via homologous recombination in ES cells.  
For selection of homologously recombined ES clones, a positive selection agent G418 
(neomycin analogue) and a negative ganciclovir (Ganc) were used. Positive selection was 
enabled by expression of the gene coding for neomycin phosphotransferase that inactivates G418 
by phosphorylation allowing only homologous recombined ES clones to survive. In the absence 
of recombination G418 blocks protein synthesis and kills the non-recombined ES cell. A 
negative selection was obtained by expression of the HSV-TK gene which is located at the 5’ 
end of the linearized targeting construct that does not integrate into the ES cell genome in correct 
homologous recombination. During non-homologous recombination events the HSV-TK 
sequence is incorporated into the genome of ES cell and thereby thymidine kinase 
phosphorylation of GanC inhibits DNA synthesis resulting in ES cell death.  
 
 
3.5.1 Knock-in targeting construct and targeting strategy 
 
A 5’ homology arm of 2.5kb, consisting of PLP gene partial Intron-I to exon-III and partial 
Intron-III, was cloned using NotI and AvrII restriction sites into the PEFRTGK12 gene targeting 
vector. The 3’ targeting arm of 6.8 Kb fragment, consisting of PLP partial intron-III, exon-IV, 
exon-V containing four Cys point mutations (C183S, C227S, C200S, and C219S), and exon-IV 
to partial exon-VII, was cloned via HpaI and XhoI restriction sites. Cys point mutations were 
introduced by the SDM. The HSV-TK sequence was located at the 3’end of the linearized 
construct (Figure 22).  
All point mutations created by SDM and all cloned exon sequences were verified by DNA 
sequencing. The organization of the construct is depicted in Figure 22. The PBS246 gene 
targeting vector with the same 5’ and 3’ targeting arms of PEFRTGK12 vector was also cloned 
and used in electroporation.   
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Figure 22: PLP knock-in targeting construct. PEFRTGK12 PLP gene targeting construct with a 2.5 kb 
left homologous arm and a 6.8 kb right homologous arm. Cys codons involved in formation of disulfide 
bridges were point mutated to Ser (C183S, C200S, C219S, C227S), depicted as red dots. The neomycin 
cassette (used for positive selection) flanked by loxP sites is present between the 5’ and 3’ homologous 
arms. The HSV-TK (used for negative selection) is located at the 3’ end of the construct.  
 
Targeting strategy 
The targeting strategy for the PLP gene locus is depicted in figure 23. In the positively 
homologous recombined clones, the endogenous PLP allele locus containing all four Cys codons 
in exon IV and V were replaced by serine codons, and a neomycin cassette flanking with loxP 
sequences is located between exons III and IV.  
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Figure 13: Schematic representation of mouse PLP gene locus targeting strategy. A) WT PLP gene 
allele B) Final targeted PLP-allele gene locus; Mutated Cys codons (red dots), Neomycin cassette flanked 
by loxP sites located between exons III and IV. 
 
 
3.5.2 ES cells electroporation and ES clones screening 
 
ES cells were transfected by electroporation (Biorad). ES cell lines V8.1 (Eggan et al., 2001), 6J 
(Tanimoto., et al 2008) and JM8.F6 (Pettitt., et al 2009) (V8.1) previously tested in gene 
manipulation and germ line transmission were used for electroporations. All ES cell lines were 
cultured on mitotically inactivated embryonic fibroblast feeders. Leukemia inhibitory factor 
(LIF) was added to the culture media to prevent differentiation of the ES cells. 2x107 ES cells in 
their exponential growth phase were used for each electroporation with 35-40µg of PLP gene 
targeting construct linearized with NotI or PvuI.  Four hours after electroporation, cells were 
selected in G418 and Ganc selection medium. 
Summary of ES cells electroporation and screening 
 
 
ES cell 
 
PLP targeting 
constructs 
Enzyme used 
for 
linearization 
 
No. of clones 
analyzed 
Homologous 
recombined clones 
obtained 
V8.1 PBS246 PvuI 210 0 
6J PBS246, PEFRTGK12 PvuI and NotI 756 (PvuI), 674 
(NotI) 
0 
JM8.F6 PEFRTGK12 NotI 454 1 
 
Table 5: Summary of electroporation and screening. 
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3.5.3 Verification of a positive ES clone 
     
 
A. I)     II)    III)   IV)                                         
 
Figure 24: Validation of ES clones for homologous recombination by PCR analysis:  
I) Targeting construct linerization: Lane I: DNA marker (NEB), Lane II: control (non-linearized targeting 
construct), Lane II: NotI linearized targeting construct.  
II) Initial screening of ES clones for homologous recombination: a 3kb PCR fragment obtained with Pre 
PLP Intron-Ia ‘sense primer’ (primer outside the 5’ end of the 5’ homology arm) and 5’Neo ‘antisense 
primer’ (primer inside the neomycin cassette) confirmed homologous recombination of the 5’ fragment. 
Non-homologous recombination yielded empty lanes. 
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Further validation of the obtained positive ES clone: Using positive ES clone DNA as a PCR template; 
 
III) Lane-I: targeted PLP allele of 4.2 Kb (homologous fragment of 3.0 kb) + neomycin gene 
sequence (1.2kb)) and WT PLP allele of 3.0 kb (homologously recombined fragment of 3.0 kb); obtained 
with primers plp intron-Ia ‘sense primer’ (outside the 5’ end of the 5’ homology arm) and PLP Ex-IV 
‘antisense primer’ (primer outside the 3’ end of the neo-cassette in exon IV).  
Lane-II: 2.7 PCR PCR fragment of targeted allele; obtained by Preplp intron-Ib ‘sense primer’ (Primer 
outside to the 5’end of the 5’targeting arm) and 5’Neo ‘antisense primer’ (primer present in the neomycin 
cassette). IV) Validation of 3’ targeting fragment: A 7.3kb PCR fragment obtained by 3’neo sense primer 
(present in the neomycin cassette) and PLP Intron VII ‘antisense primer’ (present outside towards the 3’ 
end of the 3’ homology arm) resulted in a 7.2 kb fragment confirming 3’ homology arm targeting to the 
endogenous PLP allele in the positive ES cell clone. 
 
 
3.5.4 Mutated Cys residues validation by DNA sequencing   
 
Homologously targeted ES cell clone with four Cys mutations in PLP gene allele were validated 
by DNA sequencing; The following DNA sequencing results show the replacement of the four 
Cys to Ser codons, involved in forming two disulfide bridges (Cys183-Cys 227 and Cys200-Cys 219), 
located in exon IV and V of PLP gene.  
         
48 
 
Figure 25:  DNA sequencing results of the positive ES clone. Boxes depict the exact location of four 
Cys codons (183, 200, 219, and 227) that were interchanged with Ser codons.  
 
 
3.5.5 Karyotyping of positive ES clone 
 
Karyotyping was done to exclude aneuploidy (abnormal chromosomal number). Aneuploidy 
with monosomic and trisomic conditions in ES cells can impair gene targeting and germ line 
transmission (Liu et al., 1997; Traut et al., 1984). For karyotying, ES cells were arrested at 
metaphase with colcemid and then lysed osmotically. The exposed chromosomes were stained 
with Giemsa. Chromosomes number was counted using light microscopy. Each ES cell (n=8) has 
40 chromosomes and no aneuploidy was detected. 
 
 
 
Figure 2: Karyotyping of targeted JM8.F6 ES cell clone. 
100x magnification, chromosomes are numbered arbitrarily, 
image representative of n=8 ES cells.  
 
 
 
 
3.5.6 Embryo manipulation 
 
PLP gene targeted ES clones were injected into the blastocysts to generate PLP knock-in mice. 
3.5-day post-coitum (p.c) blastocysts were isolated from super ovulated C57BL/6 pregnant mice. 
Based on the quality of the blastocysts, 10-25 ES cells were microinjected into the blastocyst 
inner-cell mass. Successfully injected blastocysts were cultured for 1 hour in the incubator for 
recovery and 6-10 blastocysts were re-implanted into each uterine horn of pseudo pregnant CD1 
mice of day 2.5 p.c. 
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Table 6: Summary of blastocyst injections and offspring obtained. 
 
 
3.5.7 Chimera validation and breeding 
 
JM8.F6 ES clones of C57BL/6N origin have been shown to have 62% germ line transmission 
efficiency and produce a black coat color (Pettit et al., 2009). Genotyping of chimeras was done 
by PCR of tail genomic DNA. Successful chimeras of mice no.1, 4, 9, 12 and 14 were validated 
as described in figure 27. Thus validated chimeric mice are currently in breeding to test germ 
line transmission and thus obtain heterozygous PLP knock-in mice.  
.                  
Figure 27: Identification of chimeric mice derived from blastocyst injected targeted ES cells. Tail 
genomic DNA from 16 pups was used for PCR with the preplp-intron-Ia sense primer (primer outside the 
5’ end of the 5’ homology arm) and 5’Neo antisense primer (primer inside the neomycin cassette in 
between exon-III and IV). The observed 3kb PCR fragment from mice no.s 1, 4, 9, 12 and 14 are 
confirmed chimeras. 
Targeted ES clone 
used for blastocyst 
injections 
No. of 
reimplanted 
blastocysts 
Obtained 
offsprings 
Positively validated 
offspring derived from PLP 
gene targeted ES cell clone 
JM8.F6 80 18 4 (male), 1(female) 
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3.6 PLP and PUFAs pivotal role in the CNS.   
 
The mouse is an excellent mammalian model system to investigate myelination, retinal function, 
and behavioral physiology. Myelin proteolipid protein (PLP) as well as the nature and ratio of 
PUFAs in the myelin phospholipids, might be essential in CNS membrane systems. They may 
also be critical for normal function of the CNS including visual and cognitive functions. To this 
end, we focused our investigations on the role of PLP in conjunction with PUFAs, by generating 
and characterizing homozygous plp-/-fads2-/- double knockout mouse/DM (DM). We describe 
here the biochemical, cellular, behavioral and myelin ultra-structural properties.  
 
 
3.6.1 Generation of plp-/-fads2-/- DM mouse (DM) 
 
Homozygous plp-/-fads2-/- mice (DM) were obtained by intercrossing PLP null and fads2 null 
single mutant mice. Since the homozygous fads2-/- mutants were infertile (Stoffel et al., 2008), 
fads2 +/- heterozygous male mice were crossed with plp-/- homozygous female mice. The thus 
obtained heterozygous (plp-/-fads2+/-, plp+/-fads2+/-) mutants were interbred to obtain DM.  
 
         
 
 
       
 
                  
 
 
Figure 28:     Schematic representation of breeding scheme for generating DM.  
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3.6.2 Genotyping and validation of DM 
 
The DM mice were confirmed by genotyping with PLP and Fads2 gene specific PCR primers 
using tail genomic DNA (Figure 29, 30). Furthermore, loss of gene transcripts was validated on 
RNA level by RT-PCR using PLP and Fads2 cDNA specific primers. Loss of protein expression 
was validated by Western blots using anti-PLP and anti-Fads2 antibodies, and loss of PLP was 
also validated by immunohistostainings of brain cryosections (Figure 30). 
Genotyping of the PLP allele in the DM was performed with PLP gene specific primers i.e., PLP 
5’UTR sense primer (5’ UTR ‘s.p’) and neomycin cassette specific antisense primer (Neo ‘as.p’) 
which resulted in a 300bp fragment for the knockout PLP allele. The WT PLP allele was verified 
with the 5’UTR sense primer (5’ UTR ‘s.p’) and a gene specific intron–I antisense primer 
(Intron-I ‘as.p’) which resulted in a 150bp fragment (Figure 30). The PLP-/- single mutant gene 
targeting has been described previously in Klugmann et al., 1997. 
PCR-genotyping of the fads2 allele of DM were performed with fads2 specific primers i.e., fads2 
5’ UTR sense primer (5’UTR ‘s.p’) and fads2 exon-I 3’end antisense primer (ex-I ‘a.p’), which 
yielded a 4.2kb fragment whereas the undisrupted WT Fads2 gene yielded a 2.6kb fragment, 
(Figure 30). Fads2-/- single mutant gene targeting was described previously in Stoffel et al., 
2008. 
 
DM gene targeted alleles         
 
Figure 3: Schematic representation of PLP and Fads2 gene targeted alleles. Neomycin cassette is 
inserted in antisense direction in both PLP and Fads2 targeted alleles.   
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Figure 30: Validation of DM mice: Genotyping was performed using tail DNA with plp and fads2 gene 
specific primers, loss of PLP and Fads2 proteins were validated using anti-PLP and anti-Fads2 antibodies 
by Western blotting. Loss of PLP was validated by immunohistochemistry in sagittal brain cerebellar 
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sections of respective mouse mutants. Immunostaining was done with anti-PLP (Cy3-red), and dapi 
(blue). 
 
 
3.6.3 Phenotyping of DM 
 
Homozygous DM mice were viable but infertile, exhibited severe skin lesions and had a 
decreased lifespan. Mild shivering started from 5 months of age and resulted most often in a 
cataleptic state. Double heterozygous mutants i.e., plp-/-fads2+/- or plp+/-fads2+/- showed no 
significant phenotypic features.  
The sterility, dermatitis and decreased life span of homozygous DM are due to the fads2-/- allele. 
Compared to fads2-/- single mutants, the DM mice were severely affected. The fertility of the 
different genotypes of the DM, homozygous and heterozygous mutants, was investigated by 
interbreeding of heterozygous or homozygous genotypes or with wild-type (C57BL/6) mice for a 
period of 4-6 months. The homozygous DM mice were infertile whereas the heterozygous plp-/-
fads2+/-, plp+/-fads2+/- mutants were fertile. Fertility status of the different mutants is shown in 
the table 7. Onset of dermatitis in DMs was observed at age 5-6 months (n=5 animals) and 
progressed rapidly throughout their lifespan, table 7. Dermatitis was observed around neck or 
face or back in the form of patches with loss of hair and superficial erosions of the skin layers 
(Figure 31). No dermatitis was observed in plp+/-fads2+/-, plp-/-fads2+/-, plp-/- or fads2-/- 
heterozygous DMs. 
The DM mice life expectancy was less than 10 months (n=6). Fads2-/- single mutants had a 
lifespan of 1 to 1.5 years and all other genotypes showed no considerable change compared with 
wild-type. A descending order of life expectancy was observed: DM < fads2-/- < plp-/-fads2+/- 
< plp+/-fads2+/- < plp-/- < wild-type (Figure 32 A). 
Body weight of all genotypes at p 24-days and 4 months were not significantly different, figure 
32b. 
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Table 7: Phenotyping of DM (plp-/-fads2-/-), single mutants (plp-/- or fads2-/-) and heterozygous 
mutants (plp+/-fads2+/- or plp-/-fads2+/-) and their wild-type counterparts. Figure 31: DM mouse 
(age 6 months / male) effected with dermatitis on neck region.  + = estimated extent of severity. 
 
      
 
Figure 32: A. Life span of different mutants monitored up to 20 months. B. Body weight measured 
at p24 and 4-months. Data represented in mean± SEM. 
 
 
 
Genotype 
Sterile/ 
fertile 
Dermatitis Cataleptic 
behavior 
Wild-type 
(CJ7BL/6) 
Fertile - - 
PLP null mutant Fertile - - 
Fads2 null mutant Sterile ++ + 
PLP+/-/Fads2+/- 
or 
PLP-/-/Fads2+/- 
 
Fertile 
 
- 
 
- 
DM Sterile +++ ++ 
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3.6.4 Gene expression analysis by semi-quantitative RT-PCR 
 
Gene expression at the RNA level and protein expression of myelin/oligodendrocyte-specific 
proteins and various PUFA biosynthesis regulating desaturases were investigated by Western 
blot and semi-quantitative RT-PCR. RNA was isolated from whole brains of 22-day-old DM, 
plp-/- single mutant and fads2-/- single mutant and compared with wild-type (C57JBL\6) mice. 
Key gene transcripts of myelin membrane and oligodendrocyte proteins in CNS, such as PLP 
and its isoform Dm20, MBP, MAG, MOG and OMgp, and neural cell adhesion molecules, 
NCAM-120 and NCAM-140, and tight junction protein connexin-43 were investigated. Gene 
expression of various major fatty acid desaturases involved in complex series of fatty acid 
desaturation and elongation steps were analyzed i.e., Fads1, Fads2, Fads3, SCD1, SCD2 and 
SCD3 RNA transcripts and likewise  CGT (UDP-galactose-ceramide galactosyl transferase), a 
key enzyme involved in synthesis of galactosphinogloipids of the myelin membrane and 
oligodendrocytes (Schulte and Stoffel, 1993).  
 
The RNA levels of Fads-3, MAG and NCAM-140 were partially down-regulated whereas Fads1 
(delta-5 desaturase) is partially up-regulated in DMs in comparison to age matched wild-type 
control. The GalC sphingolipid synthesizing CGT gene was down regulated in the fads2-/- single 
mutant compared to the plp-/- single mutant, DM and wild-type. SCD3 expression was absent in 
all genotypes since it is not expressed in brain tissue and used as a control.  
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Figure 33: Semi-quantitative RT-PCR analysis. Oligodendrocytes or myelin membrane-specific 
proteins, neuronal structural adhesive proteins, cell junction proteins as well as key fatty acid desaturases. 
GAPDH and beta-actin were used as internal loading controls. SCD3 which is not expressed in brain was 
used as a tissue specific control. Total RNA isolated from brains of p22- mice of wild-type, plp-/-, fads2-
/- and DM was employed. 
 
 
3.6.5 Brain and myelin protein analysis  
 
Whole brain protein lysates of plp-/-, fads2-/-, DM and wild-type mice, and myelin extract 
protein lysates of DM and wild-type mice, were used for Western blot analysis. Total brain 
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lysates were probed with anti-PLP, anti-Fads2, anti-MBP and anti-MAG antibodies. Myelin 
extracts were probed with anti-PLP, anti-MBP and anti-MAG antibodies. 
Protein expression analysis by Western blots revealed that, in contrast to the DM, the wild-type 
brain protein lysate contained proteolipid protein (PLP) (30 kDa) and its isoform Dm20 (26 
kDa), and the Fads2 protein (54 kDa). MBP isoforms (21, 18 and 14kDa) were detected similarly 
in all genotypes and MAG showed partial down-regulation in total protein and myelin extracts of 
DM compared to wild-type. The results of MAG gene expression at the RNA level determined 
by RT-PCR correlated well with the protein analysis data. 
   
 
Figure 34: Western blot analysis. Total brain protein extract of wild-type, plp-/-, fads2-/- and DM mice 
of p22 were used. Myelin extracts of wild-type and DM mice of 3-month-old were used. 
 
 
3.6.6 Myelin quantification 
 
Myelin was isolated from whole brains of 5-month-old wild-type and DM mice (n=3) by the 
discontinuous sucrose gradient centrifugation method (Norton and Poduslo 1973). The isolated 
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crude myelin extract was lyophilized and weighed. Myelin yield from the DM was significantly 
lower compared to wild-type. 
                                 
 
Figure 354: Myelin quantification of DM and wild-type mice. Myelin was isolated by 
discontinuous sucrose density gradient centrifugation. Data represent mean± SEM. 
 
 
3.6.7 Immunohistochemical stainings  
 
The disturbance of tight junction-associated proteins in Sertoli-cells of testis and gap-junction 
proteins in granuolosa cells of ovarian follocle of fads2-/- mutants was reported previously by 
our laboratory (Stoffel et al., 2008). In the present study, the immunolocalization and expression 
pattern of tight junction-associated proteins were investigated in cerebellum region of DM brain 
by IHC. PLP and MBP localization pattern were also investigated.   
Sagittal cryosections of brains of p22 fads2-/- and DM and wild-type were immunostained for 
occludin and ZO-1 tight junction-associated proteins using anti-occludin (polyclonal) and anti-
ZO-1 (polyclonal) antibodies. The PLP and MBP myelin-specific proteins were probed with 
anti-PLP (polyclonal) and anti-MBP (monoclonal) antibodies.  
In DM, fads2-/- and wild-type brain sagittal sections, immunoflouroscence staining of anti-
occludin and anti-ZO-1 antibodies were irregularly distributed in myelin and granular layers. In 
DM brain sections, anti-MBP antibody staining was confined to the myelin layer without any 
mislocalisation. Whereas anti-plp antibody immunostaining was not detected, which, as 
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expected, confirmed the loss of PLP expression. Thus immunohistochemistry of DM and fads2-/-
mutant brains revealed that, the tight junction proteins ZO-1 and occuludin, localization was 
inconspicuous whereas the MBP of myelin-specific, localization was not disturbed. 
 
 
 
Figure 36: Immunostaining of sagittal sections of mouse cerebellum with anti-PLP, anti-MBP, anti-
occludin and anti-ZO-1. Wild-type, fads2-/- and DM genotypes were used in the study. Sections stained 
with anti-occludin and anti-ZO-1 are 63x and sections stained with anti-PLP and anti-MBP antibodies are 
40x. ML= molecular layer; GL= granular layer; WM= white matter.  
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3.6.8 Lipid analysis 
 
3.6.8.1 Brain lipid analysis  
 
The whole brain lipid components and their fatty acid profile of 5-month-old wild-type and DM 
were analyzed. Whole brain lipids were extracted in chloroform/methanol as described 
previously. Whole lipid extracts were separated by HTPLC with solvent system 
chloroform/ethanol/water/triethylamine 35:30:7:35 (V/V/V) (Figure 37 A). Alkali-stabile lipids 
and sphingolipids were extracted from total lipid extracts and separated by HPTLC with a 
chloroform/methanol/water 65:25:4 (by volume) solvent system (Figure 37 B).  
Phosphatidylethanolamine (PE), phosphatidylcholine (PC), phosphatidylserine (PS), 
phosphatidylinositol (PI), normal fatty acid substituted galactocerebroside (GalC), α-hydroxy 
GalC (OH-GalC), GalC-derived sulfatides (sGalC) and sphingomyeliln (SPM) lipid components 
(Figure 37 A) and alkali-stabile lipid components alone i.e., SPM, GalC, sGalC, and OH- Galc 
,figure 37 B, revealed no significant expression differences between wild-type and DM (plp-/-
fads2-/-). Although the loading concentration may differ between two individual extracts the 
relative concentrations of lipid components within individual extracts were similar.  
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Figure 37: HPTLC of whole lipid extracts (right) and alkali-stable lipids; sphingolipids (left). All 
lipid bands separated on HPTLC were visualized with primulin staining. TG, triglycerides; CL, 
cardiolipin; PE, phosphatidylethanolamine; PS, phosphatidylserine; GalC, galactocerebroside; sGalC 
(GalC-derived sulfatide); PI, phosphatidylinositol; PC, phosphatidylcholine; SPM, sphingomyelin. 
 
 
3.6.8.2 Brain fatty acid profile 
 
Brain lipid fatty acid profiles i.e., saturated fatty acids, monounsaturated fatty acids and PUFAs, 
were determined by GC-MS (Gas chromatography-Mass spectroscopy). For GC-MS, total lipid 
extract was transesterified to fatty-acid methyl esters (FAMEs). FAMEs were further derivatized 
to trimethylsilyl-esters by treating with N-methyl-N-trimethylsilyl-trifluoroacetamide (MSTFA) 
for the detection of long chain-hydroxy fatty acids.  
The fatty acid profiles of wild-type and DM mice brains contained similar saturated and mono-
unsaturated fatty acids such as palmatic acid (16:0), stearic acid (18:0), docosanoic acid (22:0), 
oleic acids (18:1), eicosenoic acid (20:1) and tetracosenoic acid (24:1) as well as long carbon 
chain α-hydroxy-fatty acids such as behenic acid (OH-22:0) and lignoceric acid (OH-24:0), 
figure 38. The PUFA profile of the DM contained drastically depleted arachidonic acid (20:4) to 
2-5% and docosohexanoic acid (22:6) to 40-50%. Moreover the unusual eicosatrienoic acid 
(20:3) and eicosadienoic acid (20:2) were detected only in the DM fatty acid profile (Figure 38 
B, C). 
A, Wild-type brain lipid fatty acid methylesters 
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B. DM brain lipid fatty acid methylesters 
 
C. Wild-type and DM fatty acid profiles 
 
  
Figure 38: Fatty acid profiles of wild-type and DM. A. GC-MS chromatogram of wild-type brain 
depicting 20:4 and 22:6 PUFAs among other fatty acids. B. GC-MS chromatogram of DM brain depicting 
the unusual 20:3 and low concentrations of 20:4 and 22:6 PUFAs among other fatty acids. C. Data 
obtained from chromatograms of A and B. 
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3.6.8.3 Brain phospholipids and glycosphingolipids fatty acid profile 
 
Individual phospholipids of brain lipid extracts i.e., SPM, PE, PC, PI, and PS, and 
galactosphingolipids i.e., GalC, OH-GalC and sGalC were extracted from respective above 
HPTLC plates. Fatty acid content of individual lipid components was analyzed by GC/MS. 
PE of the DM lipid extract showed a 50% decrease in docosahexanoic acid (22:6) level and a 
large increase in eicosatrienoic acid (20:3) level with no other additional changes. PS of DM 
exhibited a 50% decrease in 22:6 and complete loss of arachidonic acid (20:4), and the PC 
exhibited only loss of 20:4, Both PS and PC showed increased levels of linoleic acid (18:2) and 
no 20:3. DM lipid fatty acids of SPM and PI showed no significant changes.  
In DM sphingolipids,  GalC fatty acid content indicated decreased lignoceric acid (24:0) and 
tetracosenoic acid (24:1) and increased linoleic acid (18:2) levels, whereas OH-GalC showed 
reduced lignoceric acid (OH-24:0) levels. In wild-type and DM the higher carbon fatty acid 
series of the galactocerebroside sulfate was not altered considerably. 
 
 
Figure 39: Fatty acid profile of individual phospholipids of wild-type and DM brains. Individual 
lipid components were analyzed by GC-MS. PE, phosphatidylethanolamine; PS, phosphatidylserine; PC, 
phosphatidylcholine; SPM, sphingomyelin; PI, phosphatidylinositol.   
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Figure 40:  Fatty acid profile of major sphingolipids. Galc (Galactocerebroside), OH-Galc (hydroxy 
fatty acid galactocerebroside), sGalC (sulfated galactocerebroside) of wild-type and DM mice brain lipid 
fatty acids were analyzed by GC-MS.   
 
 
3.6.8.4 Myelin lipid and fatty acid profile analysis  
 
Total myelin was purified from 5-month-old adult mice brain of DM and wild-type by sucrose 
gradient centrifugation method as described before. Further myelin lipids were extracted with 
chloroform: methanol, and separated on HPTLC, figure 41. All lipid components in the myelin 
extract of DM were similar to wild-type myelin lipid components.  
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Figure 41: Wild-type and DM brains myelin lipid extracts separated on HPTLC and visualized 
with primuline reagent, and their band intensities measured with image-J software.  
 
Myelin fatty acid profile analysis 
 
Brain myelin lipid fatty acid profiles were prepared similar to that from brain lipids. In contrast 
to wild-type, the DM myelin profile showed eicosatrienoic acid (20:3) and eicosadienoic acid 
(20:2) PUFAs. Myelin PUFAs of the DM were similar to that of brain PUFAs.   
                 
Figure 42: Myelin fatty acid profile of wild-type and DM mice detected by GS-MS method.  
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3.6.9 Morphology of the myelin sheath 
 
The morphology of the myelin sheath of wild-type and DM optic nerve was investigated by 
transmission electron microscopy, and p22 mice were used for the study.   
In agreement with the previous reports of plp-/- single mutant myelin structure (Boison and 
Stoffel, 1994; Montag et al., 1994; Boison et al., 1995), the electron micrographs of optic nerve 
cross sections of DM also showed the loss of compact myelin membrane multilayers around 
axons (Figure 43 B). In addition, DM also exhibited loss of thick myelin sheaths around small 
and few medium-sized axons, some extent of disordered morphology at the periaxonal collar and 
periaxonal space (white arrows), and a mild degree of hypomyelination (Figure 43 A, B, and C). 
The order of major dense lines (MDLs) and double intraperiod dense lines (IDLs) in the myelin 
membrane appeared to be undisrupted. No axonal degeneration or increase in oligodendrocyte 
number was detected. 
In the longitudinal sections of the optic nerve of the DM, at the node of Ranvier; the paranodal 
loops, paranodal bridges and juxta-paranodal regions were undisrupted, figure 43 D. The tight 
junction bridges connecting myelin and axon are also appeared to be normal.  
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Figure 43: Electron micrographs of plp-/-fads2-/- and wild-type mice optic nerves. A-C: Transverse 
sections. A: Depicting mild hypomyelination, 7000x. B-C: 30000x. D: Longitudinal section depicting 
node of Ranvier and paranodal region, 30000x, PNL= paranodal loop, PNB = paranodal loop bridges, JN 
= Para Juxtranode, IN= internode, AX = axon. Black arrow = hypomyelination of an axon. White arrow = 
abnormal myelin structures at periaxonal collar and space. WT: 9000x.  
 
 
3.6.10 Retinal morphology and function  
 
The retina is a part of CNS comprising of several layers of different types of neurons with 
synaptic interconnections. Structural morphology of the pigmented layer of retina i.e, retinal 
pigment epithelium (RPE) was investigated by electron microscopy and the retinal function was 
investigated using ERG. 
 
 
Retinal morphology 
 
The retina of wild-type and DM mice of p22 was used for transmission electron microscopy. 
Structural morphology of the RPE region along with bruch’s membrane, and photoreceptor outer 
segments was investigated. 
In contrast to wild-type, the DM retina showed a high content of apical villi like structures 
embedded with melanine granules towards the apical region of the photoreceptor outer segments 
(Figure 44, white arrows). In addition, in DM, few melanin granules were present in the RPE and 
mostly aggregated towards the apical region of photoreceptor outer segments. 
There were no other significant morphological differences observed in the RPE region i.e., in the 
thickness of the Bruch’s membrane, and structure of photoreceptor outer segments. 
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Figure 44: Electron micrographs of wild-type and DM (plp-/-fads2-/-) mice retina. Retinal pigment 
epithelium (RPE) region consisting of Bruch’s membrane (BrM), choroid capillaries (CC), thick dense 
melanin granules (M), phagosomes (P), mitochondria (m), RPE cell nucleus (N), (AV) apical villi 
projections, and outer segments of photoreceptor cells. White arrow= abnormal apical villi like structures 
observed in DM retina. 
 
 
Retinal function analysis 
 
Light induced electrical signals of the eye were measured by electroretinography (ERG). 3-
month-old wild-type and DM mice (n=4) were used for ERG. The ‘a-wave’ amplitude derived 
from photoreceptors and the ‘b-wave’ amplitude derived from Mueller cells and bipolar cells, of 
retina were recorded. Mice that were dark adapted for 24 hours were used for ERG recordings 
with single flash light of 3 and 10 minutes. In comparison to wild-type recordings, the DM 
showed a 1.5 to 2 fold decrease in a-wave readings at 3 and 10 minutes of flash light, whereas 
the b-wave amplitude was not significantly altered. The DM retinal photoreceptor outer 
segments morphology and function may play vital role in the decrease of a-wave recording and 
amplitude output.  
 
 
69 
 
      
Figure 45: Electroretinography recordings of wild-type and DM (plp-/-fads2-/-) mice (n=4). Data 
represented in mean± SEM. 
 
 
3.6.11 Behavioral physiology 
 
Behavioral physiology studies with knockout plp-/- mutant mice previously showed some extent 
of defects in neuromotor coordination (Boison and Stoffel., 1994) (Griffith et al., 1998). It is 
already known from various experiments that the lack of PUFAs may disturb behavioral and 
cognitive functions (Aid et al., 2003; Luctman and Song, 2012), but till now there are no 
experiments on mammalian models comparable to our genetic model, in which PUFA synthesis 
is lacking due to the loss  of the key fads2 desaturase enzyme expression.   
We performed various tests to study motor activity, neuromotor coordination and cognitive 
functions. Physical body movements and neuromotor coordination abilities were assessed by the 
rotarod test, horizontal rod test, inclined grid test and Morris water maze test. Cognitive 
functions such as exploratory behavior, anxiety and learning abilities were assessed by T-maze 
tests, open field test and Morris water maze test. Wild-type (n=8), plp-/- (n=8), fads2-/- (n=8), 
and plp-/-fads2-/- (n=5) mice of 5-month-old were used for the study. 
 
 
3.6.11.1 Rotarod Task (Wallace et al., 1980) 
 
The rotarod test was employed to assess the motor coordination ability. Tests were performed by 
placing mice on a rotating rod at constant speed intervals of 16rpm, 24rpm and 36rpm for 2 min 
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duration. Mice were trained for two days prior to the test, and the test was executed for two days 
consecutively. Triplicate readings were obtained on each day. 
Rotarod test revealed that there was no considerable difference in the latency time of all the 
genotypes at the low speed point of 16rpm, whereas the single mutants (plp-/- and fads2-/-) and 
the DM exhibited less latency time duration at high speed points of 24 and 36rpm compared to 
their wild-type counterparts. Motor coordination defects among different genotypes was in 
descending order; wild-type > plp-/-fads2-/- > fads2-/- > plp-/-. Results of less severe 
neuromotor defects in plp-/- mutants obtained here were consistent with the previously reported 
results of Boison and Stoffel, 1994. 
     
       
Figure 46: Rotarod task. Latency time of wild-type (C57BL/6), plp-/-, fads2-/- and DM (plp-/-fads2-/-) 
mice on rotarod. Data represented in mean ± SEM. Test performed at 16rpm, 24rpm and 36rpm speed 
points. 
 
 
3.6.11.2 Horizontal-Rod Task (Wallace et al., 1980) 
 
The dynamic balancing ability was assessed in this test. The horizontal rod test apparatus 
consists of two vertical platforms of 80 cm height and a thin metal rod of 60cm long connecting 
them horizontally. During the test, the mouse was placed on the middle of horizontal metal rod 
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with its body axis perpendicular such that it holds the metal rod with its front or back paws, and 
adjusting itself into a tension of 180° rotation. All the animals were subjected to three trials each 
day for three consecutive days. Mice were carefully observed for their paws co-ordination in 
holding the metal bar. The balancing latency time duration on the horizontal rod was recorded.  
The horizontal rod test revealed there was no considerable difference in dynamic balancing 
ability among different genotypes, moreover the balancing ability performance of fads2-/- 
mutants were higher compared to that of wild-type was due to their anxious type of behavior.  
 
          
Figure 47: Horizontal rod/bridge task. Mice latency time period on the horizontal rod (with cut off time 
of 60sec) was recorded. Data represented in mean± SEM. 
 
 
3.6.11.3 Grid Task 
 
Mice hanging ability and their paws coordination were assessed on the inclined grid. Mice need 
to balance on the grid by holding with their paws during grid mesh rotation. Mice were placed on 
the grid and then the grid inclined by 180 degrees so that the mice were hanging upside down 
holding and balancing with their paws. Mice were observed if they hang with front, back paws or 
simply falling. All the mice were measured for 120 seconds interval.  
All the mutants and WT strains showed similar balancing ability with their paws. Their grid 
hanging latency time was more than 120 seconds. 
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3.6.11.4 Open field Task (Barclay et al., 1982)   
 
Anxiety, exploratory behavior and locomotor activity parameters were assessed by open field 
test. Tests were conducted for 5 minutes duration and animals were tested for five consecutive 
days. For anxiety determination, mice location at the center or corner of the open field apparatus 
was measured during each trial. Exploratory or locomotory activity was measured by the number 
of square crossings, and rearings performed by the animal. Other parameters such as stress were 
assessed by number of groomings exhibited by the animal during the trial.  
From the open field test, based on the duration of the time that the mice spend at the center or 
towards the corners in the open field apparatus and the number of crossings and rearings 
exhibited by the mice during the test, it suggests that all genotypes showed no significant 
differences in anxiety, exploratory and locomotor behavior. The stress level assessed based on 
number of groomings were also similar among all the genotypes. 
 
    
Figure 48: Open field task. Number of square crossings, time spent at the corner and center, number of 
rearings and grooming behavior exhibited by the mice in the open field apparatus was measured during 
the trial. Data represented in mean± SEM.   
 
 
3.6.11.5 T-Maze Task 
 
A T-maze test was used to determine cognitive functions such as spontaneous alterations. The 
hippocampus region of brain plays a major role in spontaneous alterations. T-Maze apparatus is 
an ‘T’ shaped apparatus consisting of a starting long arm extended into the perpendicular right 
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and left exploratory arms, allowing the mouse to start at the long arm and to choose the left or 
right arm, which reflect the spontaneous alteration capabilities. Each mouse was tested for 30 
minutes duration and its choice of entry into the alternate arms was subsequently recorded.  
The experimental results showed that wild-type, plp-/-, fads2-/- and DM mice showed no 
differences in their spontaneous alteration in choosing subsequently the alternate right and left 
exploratory arms of the T-maze apparatus.  
 
                     
Figure 49: T-Maze task. Order of alternate selection of exploratory arms in T-Maze was recorded, 
mean± SEM is represented.  
 
 
3.6.11.6 Morris Water-Maze Task (Morris et al., 1984)  
 
Morris water maze task (MWT) is extensively used to assess cognitive functions such as spatial 
acquisition, reference memory and motor coordination defects and animal adaptability to a novel 
environment. During the test, the spatial acquisition capability and reference memory learned by 
the mouse in the novel environment were correlated to the animals learning ability and memory. 
MWT was conducted in two phases, the spatial acquisition phase and the probe trial or reference 
memory phase as follows.  
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Spatial acquisition performance 
Mice were subjected to a brief spatial acquisition with four trials each day for five consecutive 
days. The first two days were used for training the mice in the water and directing it to the 
hidden rescue platform. The escape latency time duration and swimming velocity from day three 
to five were recorded for determining the spatial acquisition capabilities.  
During the spatial acquisition phase trials, all the genotypes showed positive progress in 
acquiring spatial acquisition/learning capabilities by decreasing their latency time duration in 
finding the hidden platform. The latency time compared between different genotypes varies in 
descending order from wild-type (CJ7BL/6) > plp-/- > DM (plp-/-fads2-/-) > fads2-/-, suggesting 
that the extent of adapting spatial acquisition was lowest with fads2-/- and DM (plp-/-fads2-/-) 
mutants. In order to determine motor coordination capabilities and anxiety levels, the swimming 
velocity of all the genotypes during the trail was measured, in which the wild-type, fads2-/- and 
DM (plp-/-fads2-/-) showed similar performance, whereas the plp-/- showed lowest swimming 
velocity.  
 
  
Figure 50: Morris water maze, spatial acquisition phase results: Spatial acquisition phase trials from 
day 3 to 5 were recorded. A) Time needed to find the hidden rescue platform or escape latency time 
duration (mean± SEM). B) Swimming velocity of the mice (mean± SEM).  
 
Probe trial performance:  
 
A probe trial was carried out to determine the extent of reference memory obtained from the 
spatial acquisition phase. The probe trial was done at the end of spatial acquisition day 5 in 
absence of the hidden platform in the south quadrant. During the probe trial, the total time that 
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the mouse spent in north, south, west and east quadrants and the number of annulus crossings 
(crossings made on the platform position that was present in spatial acquisition training phase) 
were calculated. 
In probe trials, all the genotypes spent more time in the south quadrant compared to north, east, 
and west quadrants. However, in contrast to wild-type, all mutants spent less time in the south 
quadrant, suggesting that their ability for spatial acquisition was decreased. Regarding annulus 
crossings, all the mutant types i.e., plp-/-, fads2-/- and DM (plp-/-fads2-/-) showed a reduced 
number of annulus crossings suggesting low levels of reference memory compared to wild-type. 
Overall, the MWM test revealed that all mutants showed defects in their cognitive responses of 
spatial acquisition and reference memory; Among all the mutants, the fads2-/- and DM (plp-/-
fads2-/-) showed a higher extent of spatial acquisition defects (i.e., more latency time in finding 
the hidden rescue platform) and all the mutants showed similar reference memory defects. 
 
       
 
Figure 51: Morris water maze, Probe trial phase results: Probe trial; time interval that the mice spent 
in north, east, south and west quadrants in search of hidden platform (mean± SEM) average annulus 
crossings (crossings on the platform position that was present in spatial acquisition phase trails) (mean± 
SEM). 
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4 Summary of Results 
 
 
The results of this thesis can be summarized in two parts.  
 
First part: A. Investigation of Mut-PLP and Mut-Dm20 in silico hydrophobic properties, and in 
vitro and in vivo cell surface targeting. B. Mut-PLP expression regulated by Nestin enhancer, and 
transgenic mouse model generation. C. Knock-in mouse model generation lacking PLP/Dm20 
two disulfide bridges.  
Second part: Plp-/-fads2-/- double-mutant mouse model (DM) generation and characterization, 
addressing the role of complex structural assembly of CNS myelin proteins and lipids.  
 
 
First Part: 
 
A. In silico structural and hydrophobic properties, and in vivo and in vitro cell surface targeting 
were investigated of PLP and its splice variant Dm20, and their mutated forms i.e., Cys-mut PLP 
(Mut-PLP) and Cys-mut Dm20 (Mut-Dm20). PLP and Dm20 cDNA fragments were initially 
synthesized from mRNA of WT mouse brain. Site-directed mutagenesis was used to introduce 
point mutations of Cys with Ser codons at defined locations in PLP and Dm20. A total of 19 PLP 
and Dm20 cDNA constructs were generated, table 3. From this pool, WT-PLP, WT-Dm20, Mut-
PLP (Cys-less PLP) and Mut-Dm20 (Cys-less Dm20) cDNA fragments were used for further 
investigations.  
In silico prediction of protein transmembrane orientation and hydrophobic properties, based on 
Kyte-Doolittle hydrophobic plots and the amino acid hydrophathy index, were analyzed for WT-
PLP, Mut-PLP, WT-Dm20, and Mut-Dm20. Kyte-Doolittle plots revealed a partially disturbed 
conformation of Mut-PLP, in other word an alteration in the PLP specific domain loop 
orientation in the lipid membrane in comparison to the WT-PLP. No considerable disturbances 
were observed among Dm20 mutant and WT forms. Hydropathy index values obtained from 
SOSUI program resulted in the following descending order of hydropathy: WT-Dm20>Mut-
Dm20>WT-PLP >Mut-PLP, revealing the reduced hydrophathy index values for Mut-Dm20 and 
Mut-PLP compared to their WT counterparts.  
77 
 
Intracellular trafficking and membrane targeting of WT-PLP, Mut-PLP (Cys-mut PLP), and 
Mut-Dm20 (Cys-mut Dm20) under in vitro and in vivo conditions were investigated. WT-PLP-
EGFP, Mut-PLP-EGFP and Mut-Dm20-EGFP constructs were generated accordingly and used 
for transfection of COS-7 cells for in vitro studies. WT-PLP-EGFP protein was transported to the 
plasma membrane, and could be detected in the filopodia or microspikes, endoplasmic reticulum 
(ER), and Golgi apparatus, but intriguingly, the Mut-PLP-EGFP and Mut-Dm20-EGFP were 
detected only in ER and the Golgi apparatus and not at the plasma membrane or in filopodia-like 
structures.  
To investigate the intracellular trafficking of WT and Mut-PLP under in vivo or native 
conditions, primary oligodendroglial progenitor cells were isolated from 6-8 day-old neonatal 
plp-/-mice and transfected with WT-PLP-EGFP and Mut-PLP-EGFP constructs. 
Immunocytochemistry showed that WT-PLP-EGFP was transported and integrated into the 
plasma membrane but interestingly, the Mut-PLP-EGFP was not transported or integrated at the 
plasma membrane.  
B. In order to investigate the regulation and expression of Mut-PLP under the Nestin enhancer 
gene element in early stages of CNS development, initially a preliminary NesMut-PLP construct 
was generated. Its expression was validated by stable transfection into OLN93 oligodendrocyte 
cells. Semi-quantitative RT-PCR revealed that NesMut-PLP transfected OLN93 oligodendrocyte 
cells had two folds of higher expression level of mutant PLP compared to the untransfected 
OLN93 cells. Subsequently, an Nh/MBPMut-PLP transgene construct containing the Nestin 
enhancer together with a MBP promoter, Mut-PLP, and an IRES separated EGFP was generated. 
This transgene construct was microinjected into pronuclei of fertilized plp-/-mouse eggs. The 
resultant transgenic mice are currently under investigation. 
C. To investigate the structural and functional role of the two disulfide bonds in the PLP’s 
extracellular loop in vivo, a knock-in mouse mutant is being generated by a gene targeting 
approach. A targeting construct containing PLP gene homologous targeting arms, containing 
four point mutated Cys codons i.e., C183S, C227S, C200S, and C219S (involved in the 
formation of di-sulfide bonds) in exon IV and V, was generated. The neomycin cassette flanked 
with Cre-LoxP sequences was present between 5’ and 3’ homologous targeting arms of the 
targeting construct. The neomycin-cassette was used as a selection marker and for PCR 
validation during the process of homologous-recombinant ES cell clones screening. In the 
obtained positive ES clone, the Cys mutations and correct homologous recombination were 
confirmed by PCR and DNA sequencing. Karyotyping was also performed and no chromosomal 
aberrations were detected. The homologously targeted ES clone was injected into blastocysts 
isolated from CJ7BL/6 mice and re-implanted into foster mothers. Among nineteen (19) 
offsprings obtained, five (5) were identified as positive chimeras, which are currently in breeding 
to obtain PLP knock-in heterozygous mice. 
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Second part: 
 
DM (plp-/-fads2-/- double mutant) mice were generated by crossing plp-/- with fads2+/- single 
mutants. Validation of the DM mice was done by PCR-genotyping with PLP and Fads2 gene 
specific primers. Furthermore, absence of PLP and Fads2 in the DM was confirmed on RNA and 
protein level. Absence of PLP was also confirmed by immunostaining of DM brain cryosections 
with anti-PLP antibody. Phenotypes exhibited by the DM included reduced lifespan, severe 
dermatitis and sterility: DM mice had a reduced life span of less than 10 months compared to the 
plp-/- (20 months) and fads2-/- mice (>16 months). DM also showed extensive dermatitis 
compared to age matched fads2-/- single mutant mice. Likely due to infertility in the fads2-/- 
mice, the DM were also infertile. Moreover, partial tremors and seizures were observed in the 
adult DM starting from five months of age. 
The expression of various myelin/oligodendrocyte specific protein gene transcripts such as PLP, 
MBP, MAG, MOG and OMgp, and gene transcripts of fatty acid desaturases such as Fads1, 
Fads2, Fads3, SCD1, SCD2, SCD3, and cell adhesion molecules such as NCAM-120, NCAM-
140, along with tight junction protein CX-43 were investigated in the brain tissue of wild-type, 
plp-/-, fads2-/-, and DM mice by semi-quantitative RT-PCR. Gene transcription levels were 
found to be similar between all the genotypes except the MAG gene transcript which was 
partially down-regulated in DM compared to wild-type (BL6CJ/7), whereas single mutants of 
plp-/- and fad2-/- showed normal expression of MAG. The level of myelin protein expression 
was investigated by Western blotting using anti-PLP, anti-MBP, and anti-MAG. MAG 
expression was partially down-regulated in DM, compared to wild-type. To determine potential 
disturbances in the localization of myelin specific proteins and tight junction proteins in the brain 
cryo-sections of wild-type, fads2-/- and DM, were immunostained with myelin specific anti-PLP 
and anti-MBP, and tight junction specific anti-occludin and anti-ZO-1 antibodies. Inconspicuous 
differences were observed in the localizations of occludin, ZO-1, whereas the PLP and MBP are 
confined to the myelin region of the cerebellum.   
Whole brain and myelin lipid components were extracted from adult wild-type and DM and 
analyzed by HPTLC. All the major lipid components i.e., phosphatidylethanolamine (PE), 
phosphatidylcholine (PC), phosphatidylserine (PS), phosphatidylinositol (PI), sphingomyelin 
(SPM), galactocerebrocide (GalC) and sulfated Galc (sGalC) were detected at similar expression 
levels with no significant differences between wild-type and DM lipids. Furthermore, the fatty 
acid profile of the whole brain and myelin lipid extracts of wild-type and DM were analyzed by 
GC-MS. In contrast to wild-type, in the DM, arachidonic acid (20:4) and docosahexanoic acid 
(22:6) levels were depleted drastically, and the unusual PUFAs i.e., eicosatrienoic acid (20:3) 
and eicosadienoic acid (20:2) were detected instead. Fatty acid species of individual 
phospholipid and sphingolipid components of wild-type and DM brain tissues were also 
analyzed by GC-MS. In contrast to wild-type, in DM the PE contains higher 20:3 levels, whereas 
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PC and PS contains high 18:2 levels, compensating for the decreased levels of 20:4 and 20:6 
PUFAs in PE, PC and PS. 
Myelin morphology of the optic nerve of p22 wild-type and DM mice was investigated by 
electron microscopy. The DM differed from WT, and showed perturbation of myelin sheath 
morphology including the periaxonal space and periaxonal collar around few axons. 
Furthermore, a certain degree of hypomyelination was also detected, whereas the paranodal 
region at the node of Ranvier was not disturbed.  
Retinal morphology and function in p22 wild-type and DM mice was investigated by electron 
microscopy and electroretinography (ERG), respectively. In contrast to wild-type retinal 
morphology, the DM mice showed apical villi like structures with embedded melanin granules 
towards the apical region of the outer segments. The electroretinography (ERG) recordings of 
DM showed two fold decrease of a-wave amplitude at 3 and 10 minutes flash light in contrast to 
wild-type. 
Behavioral physiology, such as neuromotor coordination and cognitive abilities, of wild-type, 
plp-/-, fads2-/-, and DM mice was investigated with rotarod, inclined grid, horizontal rod, T-
Maze, open field and Morris water-maze tasks. Rotarod and Morris water-maze tasks revealed 
significant defects in motor coordination of all mutants compared to wild-type. Inclined grid and 
horizontal rod tasks used in assessing the balancing ability showed no significant differences 
among all the genotypes including wild-type. T-Maze task also showed no significant differences 
in spontaneous alterations among different genotypes. The open field task used in assessing the 
anxiety type of behavior showed similar pattern of anxiety among different genotypes. The 
Morris water-maze task revealed that all mutant genotypes compared to the wild-type, showed 
considerable defects in their cognitive ability i.e., spatial acquisition and reference memory. 
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5 Discussion  
 
 
5.1 Cys residues are critical for PLP and Dm20 targeting to the cell surface  
 
PLP and its isoform Dm20 are strictly conserved regarding their intracellular trafficking and 
plasma membrane targeting, and have specific structural and functional roles in myelin 
morphology. Along with the structural role of PLP and Dm20 in myelin compaction, their cell 
surface targeting in oligodendrocytes is critically important since defects in their targeting to the 
cell surface may result in a broad spectrum of X-linked dysmyelinating disorders such as PMD 
and SPG2.  The PLP/Dm20 Cys residues are involved in posttranslational modifications such as 
thio-acylation and in the formation of two disulphide bridges present in the extra cellular loop-II. 
Post-translational modifications such as thio-acylation play a critical role in protein 
transportation and sorting. Similarly, the post-translational modifications of PLP/Dm20, i.e., 
thio-acylation and the formation of two disulfide bridges might be essential for proper protein 
folding and targeting to the plasma membrane. Previously it was reported that truncated 
fragments of PLP, i.e. a peptide containing the N-terminal 13 amino acids of PLP, containing 
only three fatty acyl chains, fused to LacZ (Wight et al., 1993) or to EYFP (Schneider et al., 
2005), is sufficient  for PLP trafficking to the plasma membrane. There are also reports regarding 
some PLP/Dm20 Cys point mutations that could correlate with the PMD phenotype. Here, we 
investigated the significance of Cys residues of PLP and Dm20 in cell surface trafficking.  
The influence of PLP Cys residues in intracellular targeting was studied by generating mutant 
forms of PLP and Dm20, Cys-mut PLP (Mut-PLP) and Cys-mut Dm20 (Mut-Dm20) constructs, 
in which all Cys residues were substituted by Ser residues and fused with an EGFP tag for 
intracellular localization. Furthermore, using transfection studies of Mut-PLP and Mut-Dm20, 
we could determine that the lack of Cys residues impaired normal trafficking of both isoforms. 
Interestingly, Mut-PLP and Mut-Dm20 were retained in the ER or Golgi and neither isoforms 
were detectable at the plasma membrane under in vivo or native and in vitro conditions. This 
implies that PLP and Dm20 Cys residues, their S-acylation and disulfide bridge formation are 
crucial for exit from the ER or Golgi and targeting to the plasma membrane. Moreover, the 
disulphide bridges in the extra-cellular outer loop region of PLP and Dm20 may have a 
prominent role in stabilizing the extra-cellular loop and thus overall PLP conformation, which 
may in turn be critical in proper cell surface targeting. On the other hand, WT-PLP and WT-
Dm20 are integral transmembrane proteins and are strongly hydrophobic. By using an in silico 
protein structural prediction i.e., based on kyte-doolittle hydropathy plots, we could determine 
that Mut-PLP and Mut-Dm20 are likely to exhibit an impaired intracellular loop structural 
conformation along with decreased hydrophobicity, which may affect their integration into the 
81 
 
lipid bilayer during trafficking to the cell surface. Impaired hydrophobic properties of 
PLP/Dm20 might also affect their proper vesicular membrane internalization for trafficking from 
the Golgi apparatus to the cell surface. 
 
 
5.1.1 Similar trafficking of Mut-PLP and Mut-Dm20 in COS-7 cells and PMD 
 
The underlying intracellular trafficking defects of PLP and Dm20 under in vitro conditions may 
shed light on the in vivo PMD phenotype. Moreover, the differential trafficking between PLP and 
Dm20 under in vitro conditions in COS-7 cells might correlate with the extent of PMD severity, 
i.e. impaired sorting of both PLP and Dm20 isoforms to the cell surface could result in severe or 
connatal PMD, whereas only Dm20 targeting to the plasma membrane could result in the less 
severe or classical PMD (Gow and Lazzarini, 1996). Similarly, in our in vitro COS-7 cells assay 
we could show that the intracellular trafficking of Mut-PLP and Mut-Dm20 was similar. Both 
mutant isoforms could not be detected at the cell surface, which might be a prominent feature of 
the severe or connatal PMD phenotype under in vivo conditions.  
 
 
5.1.2 Differential trafficking in vitro and in vivo 
 
The present study has been conducted in heterologous system in vitro i.e., COS-7 cells and in 
homologous or native system in vivo i.e., in primary oligodendrocytes that were isolated from 
neonatal PLP-null mice. Both cell lines were of a PLP null background and are perfect models. 
Although COS-7 cells are heterologous and immortalized cells compared to primary cultures of 
oligodendrocytes of glial lineage used in this study, the intracellular trafficking of wild-type and 
Mut-PLP in COS-7 cells is similar to primary cultures of oligodendrocytes, revealing that the 
targeting strategy may not be restricted to native cell types.  
The importance of palmitoylation in protein sorting has also been well demonstrated with several 
other proteins such as PSD-95. PSD-95 is a neuronal transmembrane protein regulated by its N-
terminal palmitoylation for trafficking from the neuronal cell body to destined postsynaptic 
densities (E1-Husseini et al., 2000a). 
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5.1.3 Cys-mut PLP (Mut-PLP) expression in early CNS developmental stages  
 
In contrast to PLP expression in oligodendrocytes and its critical role in myelination, Mut-PLP 
expression in the early glial lineage and subsequent precursors reveals its specific functional role 
in myelinogensis and myelin morphology under in vivo conditions. From various transgenic 
mouse models it has been shown that the Nestin second intron enhancer is highly specific 
towards early brain development and in early and late precursors of the oligodendroglial lineage. 
In the present work, we validated Nestin enhancer regulation on Mut-PLP and a transgenic 
mouse is being generated, as discussed below.  
 
 
5.1.3.1 Validation of Nestin enhancer regulation of Mut-PLP  
 
To validate the Nestin enhancer gene element on Mut-PLP in vitro, Mut-PLP was over-expressed 
under the control of the Nestin enhancer gene element together with the TK-promoter in 
immortalized oligodendrocytes or OLN93 cells. Investigation of the levels of over-expression 
indicated a two fold increase in Mut-PLP expression. This suggested that the Nestin enhancer is 
an active gene regulatory element capable of regulating Mut-PLP. Previously, it was reported 
that Nestin is down-regulated in differentiating oligodendrocytes (Almazan G et al., 2001), here 
we have demonstrated that the Nestin enhancer may facilitate over-expression of Mut-PLP in 
OLN-93 cells which are capable of expressing myelin specific genes and are of glial lineage. 
 
 
5.1.3.2 Generation of a transgenic mouse expressing Mut-PLP regulated by the Nestin 
enhancer region. 
 
The Nestin enhancer was used with the MBP promoter as a gene regulatory element enabling 
expression of Mut-PLP in early CNS development specifically in the oligodendrocyte lineage. 
Previously, the MBP promoter was well characterized as a strong promoter, active in early 
embryonic CNS development and in the glial lineage. The transgene construct used in generating 
transgenic mouse mutant also contains an IRES sequence and an EGFP marker. The IRES 
sequence present in between Mut-PLP and EGFP sequences was predicted to facilitate 
independent translational initiation of Mut-PLP and EGFP under the same cis-regulatory element 
and enables us to investigate the functional role of Mut-PLP independent to that of EFGP. The 
EGFP marker could be used in tracking the Mut-PLP expression pattern in different stages of 
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CNS brain development and in subsequent oligodendroglial lineage. The transgenic mutant is 
being generated by injecting the transgene into the pronuclei of oocytes. To eliminate 
background of endogenous wild-type PLP/Dm20 expression in the transgenic mutant, we 
injected the transgene into the pronuclei of PLP-null mouse oocytes. Thus, the transgenic mouse 
mutant is still being produced is currently under obtaining founder mice.  
 
 
5.2 Knock-in mouse mutant of PLP/Dm20-lacking disulfide bridges  
 
PLP and Dm20 have two disulfide bridges, i.e., Cys183-Cys227 (proximal disulfide bridge) and 
Cy200-Cys219 (outer disulfide bridge), in their extra cellular loop-II. Recently, it was reported 
that a patient with a point mutation in PLP Cys codon (C183R) which is involved in proximal 
disulfide bridge formation, exhibited the classical PMD phenotype (Fukumura et al., 2011). It is 
speculated that this lack of disulfide bridges in the extra cellular loop of PLP may influence PLP 
structural conformation, which results in its misfolding and ER retention due to prolonged 
binding with the ER calnexin chaperone. Prolonged binding with calnexin may accumulate PLP 
in the cytoplasm, which is possibly toxic and further resulting in apoptosis of oligodendrocytes 
leading to PMD. Recently, it was also shown in vitro in COS-7 cells, that PLP retention in the 
ER is due to the PLP extra cellular loop free Cys residue cross linkages in the ER. It has been 
suggested that of two disulfide bridges in the extra cellular loop of PLP/Dm20, only the proximal 
disulphide bridge is important for ER quality control and exit (Dhaunchak and Nave, 2007). For 
investigating the role of Cys bridges of PLP/Dm20 in CNS and specifically on the myelin 
phenotype, a knock-in mouse mutant is being generated.  
A gene targeting approach is being used to generate a knock-in mouse mutant in which the two 
disulfide bridges (proximal and outer bridges) of PLP/Dm20 are deleted. Thus the knock-in 
mutant mouse is still being produced, which is currently at chimera breeding step.  Since the PLP 
knock-in mouse mutant is being generated by altering the endogenous PLP gene locus at 
confined Cys codon positions, instead of wild-type PLP expression, only PLP and Dm20-lacking 
two disulfide bridges in their extra cellular loop should be expressed. Moreover, in the PLP 
knock-in mutant, expression of the PLP/Dm20-lacking disulfide bridges would be obtained 
under endogenous wild-type PLP gene regulatory elements.  
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5.3 The role of PLP and PUFA in the CNS  
 
The CNS myelin membrane is composed of unique proteins such as PLP, and has a high lipid 
content including phospholipids which account for 40-45% of total lipid content. PUFAs such as 
docosahexaenoic acid (DHA) and arachidonc acid (AA) are the major components of the 
phospholipids in the myelin membrane and in the brain (Youdim et al., 2000). In the CNS 
myelin, PLP and major PUFAs play critical structural and functional roles. Lack of PLP and 
PUFA in phospholipids, in CNS myelin membrane could reveal their direct impact in the CNS; 
that is on myelin membrane morphology, biochemical and cellular functions and in relation to 
behavioral physiology. Therefore a plp-/-fads2-/- double knock-out mouse mutant has been 
generated and characterized in the present work.  
The genetically defined plp-/-fads2-/- double knock-out mouse (DM) was validated on the 
genomic, mRNA and protein level. The DM brain fatty acid profile showed drastically depleted 
major PUFAs. Intriguingly, the DHA quantity levels were depleted only to 50-60%. Despite lack 
of Fads2 and thus the in vivo PUFA synthesizing function in the DM, the maintenance of high 
DHA content in the brain was possibly due to accumulation of DHA from the diet or through 
cross reactive pathways, which require further investigation. The maintenance of high DHA 
levels in the brain of the DM should be considered in light of previously reported DHA 
conservation in the brains across several vertebrate species (Anderson et al., 1990; Tinoco et al., 
1982), this supports the importance of DHA as structural entities in the membrane phospholipids, 
or as precursors of docosanoids, etc.  
The DM fatty acid profile showed elevated levels of unusual eicosatrienoic acid (20:3), and a 
high level of eicosadienoic acid (20:2), which is in agreement with the fads2-/- single mutant 
fatty acid profile reported by Stroud et al., 2008. Stroud et al., 2008 speculated that 20:3 could be 
catalyzed from the fatty acid derivative of linoleic acid by delta-5 desaturase/fads1 in the absence 
of delta-6 desaturase/fads2, which is also possible in our DM. Based on the PUFA profile of DM 
brain tissue, we propose that the elongase and delta-5 desaturase catalyze an unusually high level 
of 20:3 and 20:2 PUFAs from 18:2 (linoleic acid/n-6) and the lack of major PUFAs synthesis, as 
depicted in Figure 52. The exact sequence of delta-5 desaturase and elongase catalysis in the 
pathway could be verified based on 20:3 and 20:2 structures, which is still under investigation.  
The elevated level of 20:3 in the DM brain might be essential for compensating the depleted 
level of 20:4 (n-6) and 22:6 (n-3) in the membrane phospholipids and in eicosanoid synthesis.  
Of the fatty acid profile of individual major phospholipids in DM brain lipids, major PUFAs 
including 20:4 (eicosatetraenoic acid) and 22:6 (docosahexaenoic acid) are depleted in 
phosphatidylethanolamine (PE), phosphatidylserine (PS), and phosphatidylcholine (PC). 
Interestingly, the depleted major PUFAs 20:4 and 22:6 were substituted with the unusual 20:3 in 
PE, whereas they were substituted with 18:2 in PS and PC. Substitution of the critical 20:4 and 
22:6 with unusual 20:3 primarily in PE, might be due to the higher PE content among the myelin 
membrane phospholipids and its involvement in various pathways. Thus, overall depletion of 
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PUFAs in major phospholipids such as PE, PS, and PC, may in turn reduce unsaturation levels 
and increase the saturation index, decreasing myelin membrane fluidity and thus perturbing its 
functional role. 
 
 
Figure 52: Proposed desaturation and elongation of the PUFA synthesizing cascade in the DM 
brain, based on its PUFAs profile. 
 
 
The DM exhibited profound defects in its CNS myelin morphology. DM showed myelin 
morphological defects such as hypomyelination with reduced myelin thickness, loss of myelin 
compaction, architecture and reduced overall myelin production in the CNS. The significant 
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reduction in the total CNS myelin quantity in the DM brain is also a prominent feature for 
hypomyelination condition. Since PLP together with the PUFA are the major structural 
constituents of the myelin membrane, their absence might had profound effect on myelin 
membrane biosynthesis, myelin membrane fluidity or saturation index and on its biophysical 
properties. Furthermore, as observed in the electron micrographs of DM CNS myelin, the myelin 
paranodal junctions were not disturbed. In contrast to previous report (Stoffel et al., 2008) of 
disturbance of tight-junction association proteins in the Sertoli cells of testis and gap junction 
proteins in ovarian follicles due to the lack of PUFA, here the undisrupted paranaodal junction 
observed in the myelin of DM might be due to the conserved levels of DHA in the CNS myelin 
membrane phospholipids compared to testis. 
Based on in vitro experiments in oligodendrocytes it was shown that PUFA supplements could 
alter the myelin protein expression level, and could impact oligodendrocytes plasma membrane 
filopodia-like structures. In contrast, in our present in vivo study, the myelin proteins (MBP, 
MOG and MOBP) mRNA expression levels were not significantly altered in the DM brain. 
Although MAG was only 0.5 fold down-regulated at the mRNA and protein level in DM in 
contrast to the single mutants and wild-type counterparts, apart from its partial role towards 
axon-glial contact, its major role in the myelin membrane is unknown. Fatty acid synthesizing 
desaturase isoforms of FADs and SCDs were also investigated in the DM. In the PUFA 
synthesizing pathway, there is competition between n-3 and n-6 FAs for the same elongases and 
desaturases, and there are multiple desaturase isoforms which are expressed in a tissue specific 
manner. It has also recently been shown that one of the isoforms of fads, fads3, is up-regulated 
during LC-PUFA supplementation in vivo (Reardon ht et al., 2012). However, in the present 
study we did not observe any changes in the mRNA expression levels of various desaturase 
isoforms, i.e., Fads1, Fads2, Fads3, and Scd1 and Scd2, in the DM brain tissue. Regarding 
critical myelin specific proteins such as NCAM (both isoforms i.e., NCAM-120 or NCAM-140), 
major myelin lipid GalC synthesizing enzyme CGT, and tight junction protein connexin-43, no 
major or significant expression differences were observed. This may suggest that the myelin 
proteins, desaturases and their isoform expression are highly regulated. Moreover, the PLP and 
delta-6/fads2 functions may not be substituted by other myelin specific proteins or desaturases in 
the DM. 
It was also previously reported that various mouse mutants, such as plp-/-, fads2-/-, mag-/-, and 
plp-/-mbp-/-, also have no major significant changes in their critical myelin protein gene 
expression profile nor compensate their  functions (Stoffel et al., 1997, Uschkureit et al., 2000; 
Stroud et al.,2009). This is in agreement with our observed results with the DM brain gene 
expression profile.  
Photoreceptor outer segments in the retina contain high DHA and AA content in membrane 
phospholipids. In the DM, the photoreceptor outer segment and RPE region morphology were 
not significantly perturbed but mild distortions in the arrangement of apical villi in apical RPE 
region were observed. Functional assessment of retina function by ERG revealed a two-fold 
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decrease in ERG a-wave amplitude in the DM in contrast to the wild-type. Thus, the partial level 
of apical villi disturbance or its undetected structural morphological alterations might have 
shown an effect in decreasing ERG a-wave output. We can also speculate that the lack of PUFA 
content, especially DHA and AA, might have shown defects in the underlying molecular electro-
chemical signaling cascades. Moreover, although the photoreceptor outer segments were 
composed majorly of DHA and PUFAs in their membrane phospholipids, they appeared to be 
normal in the DM, which awaits further molecular level investigation. 
Among the phenotypic features of the DM, the sterility and skin-dermatitis were also observed in 
fads2-/- single mutants and therefore are likely contributed from the fads2-/- single mutants. The 
DM also exhibited additional phenotypic features in contrast to their single mutants, such as 
apathetic behavior, partial but significant tremors and seizures, starting from 5 months. The DM 
mice also had a profound reduction in life span. These features of DMs may be correlated to its 
membrane systems morphological phenotypic defects i.e., hypomyelination disorder observed in 
the CNS. These observed phenotypic features are also in close agreement with the PMD or SPG2 
disease condition where CNS hypomyelination or dysmyleination are the prominent features. 
The motor coordination assessed by rota-rod and the Morris water maze-based swimming 
velocity parameter revealed partial but statistically significant defects in DM (plp-/-fads2-/-) and 
in plp-/- and fads2-/- mouse mutants compared to wild-type. Previously, it was reported that plp-
/- mouse mutants with CNS myelin compaction defects have partial neuromotor coordination 
defects (Boison and Stoffel, 1994; Gutierrez et al., 1995). It was also reported that the CGT-null 
mutant with dysmyelinosis exhibited profound hind limb paralysis and motor coordination 
defects. Similarly, the CNS myelin defects in the DM, specifically the loss of myelin compaction 
phenotype derived from plp-/- mutant might have contributed to the DM mice neuromotor 
coordination defects. The cognitive abilities, specifically the acquisition ability and the reference 
memory, were partially decreased in all the mutants including the DM mice in contrast to wild-
type counterparts. It has been shown that the deficiency of myelin i.e., in the case of shiverer 
mutant or MBP null mutant, could decrease learning ability (Inagawa et al., 1988). Moreover, it 
has been also well documented that the cognitive abilities could also be correlated to CNS 
myelin disorders such as dysmyelination, hypomyelination, neurodegenerative disorders such as 
MS, and ageing. Hence we can speculate that the DM containing CNS myelin morphology 
defects such as hypomyleination, and depleted major PUFA conditions have contributed towards 
its cognitive impairment. 
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6 Materials and methods 
 
 
6.1 Cell culture methods 
 
 
6.1.1 Oligodendrocytes preparation and transfection 
 
Primary oligodendrocytes preparation: 6 to 8 day-old 3-4 plp-/- mice were scarified, and 
appropriate quantity of brains were dissected and used according to the oligodendrocyte 
preparation kit (MACS, Miltenyi); Initially brain cells were dissociated with gentle Macs 
Dissociator (Miltenyi) and further immature or mature oligodendrocytes were purified with anti-
O4 micro beads (Miltenyi) using MACS separator (Miltenyi). Thus separated and purified 
cultures containing pre or mature oligodendrocytes (Cizkova et al., 2009; Jungblut et al., 2012) 
were supplemented with Macs neuro-supplement media (Miltenyi) accordingly for further use.   
Culturing conditions and transfection: Pre-oligodendrocytes were incubated (at 37°C and 5% 
CO2) in 24-well plates with MACS-neuro medium (Miltenyi Biotech) containing 10µg/ml 
penicillin/streptomycin. Transient transfection was carried out with NanoJuice liposome 
transfection reagent (Novagen) according to the manufacturer protocol. 
 
 
6.1.2 ES cell culture 
 
ES-cells were incubated (at 37°C and 5%CO2) in DMEM medium; containing 15%FCS, 
100mg/ml penicillin/streptomycin, 0.03%glutamine, 1250ULIF, and 1mM 2-mercapthoethanol. 
ES-cells were cultured on embryonic fibroblasts. 
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6.1.3 Electroporation and Selection of ES cells 
 
ES-cells in active growth phase and in culture for at least two days were used for electroporation. 
Four hours before electoporation, the medium was changed. 30-40µg of the linearized targeting 
vector was used for ES cells electroporation; Approximately 2x107 ES cells were washed twice 
with PBS (Ca2+ and Mg2+free), and trypsinized as follows: Cell were incubated with 3 ml 
trypsin/EDTA (0.05%) for 3-5 min at 37°C. After incubation, trypsin reaction was stopped by 
adding 7ml of ES medium and resuspended until a single cell suspension is formed and 
sedimented at 1000rpm for 4 minutes. The supernatant was carefully removed and the pellet was 
diluted with appropriate volume.  
ES cells were counted, and 1.2-1.5 x 107 cells were resuspended in 800µl of PBS with 30-40µg 
of linearized DNA and transferred into a 0.4cm electroporation cuvette (BIORAD), and the rest 
of the cells were used as control. Electroporation was carried out with a pulse of 500V and 230µf 
at RT. After five minutes of incubation at room temperature or on ice, the electroporated cells 
were transferred into 10ml of ES wild-type medium, resuspended, and the medium was 
distributed equally to five 90mm cell culture petri dishes seeded with fibroblast cells (2x106 cells 
/ plate). 
 
 Selection of ES cell clones 
 
24 hours after electroporation, the ES cell medium was replaced with the G418-containing ES 
medium for 5 days. After 5 days, the G418 containing medium is replaced by ganciclovir-
containing medium and cultured for 5 days. The selection resistant ES clones were manually 
picked. 
 
Isolation of the ES cell clones 
 
Plates containing ES cell clones were washed with PBS and picked manually under microscope, 
and transferred to the 96-cell culture plates. 96-cell culture plates containing clones were 
immediately trypsinized for detachment, and transferred to 96-well plate seeded with embryonic 
fibroblasts. After 3-4 days of culture, cells were trypsinized. 50% of cells were transferred to 
gelatin coated 96-well plates which were used for the isolation of genomic DNA and the 
remaining 50% were cryo-preserved.  
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6.1.4 Karyotyping of ES cells 
 
ES cells cultured on gelatinized 90mm round petri-dishes were used in karyotyping as follows: 
1. Cell cycle arrest by colchicine treatment 
a. To  5ml of medium in a 90mm petri dish containing ES cells, 33µl of colchicine solution 
(Demecolcine solution, Sigma) was added  
b. Allowed incubation for 50 min at 37°C. 
2. Cells were washed 3 times with PBS, and detached with trypsin  
3. Osmolysis with hypotonic KCL solution (0.56%) 
a. Cells were centrifuged for 8 min at 500g, and the supernatant was discarded 
b. 1ml of KCl was added drop wise to the precipitate for osmolysis 
c. 3ml KCl was added and cells were resuspended carefully  
d. Cell were incubated for 8-10min at room temperature, and centrifuged for 5min at 500g 
and the supernatant was discarded. 
4. Fixation  
a. In the residual liquid cells were gently re-suspend 
b. 2 ml of ice-cold fresh fixative [methanol / acetic acid (3:1)] was added drop wise 
c. Incubated for 5 min at RT and centrifuged at 500g for 5min, and supernatant was 
aspirated 
d. Steps a to c were repeated for 1 to 2 times, the final precipitate was dissolved in 0.5-1 ml 
fixative solution 
e. Cells were dropped from a Pasteur pipette from at least 30cm height on a clean 
microscopic slides and allowed to dry 
 
5. Staining 
a. Slides were immersed in giemsa staining solution  (Giemsa stain, GS-500, Sigma) 
b. Washed with water, air dried, and mounted with mounting media (Merck). 
Chromosomes of individual cells were examined at 63X magnification.  
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6.1.5 Cryopreservation of ES cells and COS-7 cells   
 
Freshly prepared ice cold freezing medium (Wild type-cell culture medium with additional 20% 
FCS, and 10% DMSO, or as prescribed) was used for cryopreserving the cells. To the 96-well 
plate containing ES-cells in 50µl of wild-type medium, freshly prepared ice cold freezing 
medium of 50µl was added and the plate immediately wrapped in an  aluminum foil and 
transferred initially to -20°c for 24 hrs and finally to -80°C.  
 
 
6.1.6 Thawing and expansion of ES-cells and COS-cells 
 
For thawing and expanding, the frozen 96-well plates or 1 ml tubes from -80°C were transferred 
and incubated at 37°C or at RT for 3-6 min. According to the frozen medium used initially in 
cryo-preserving, two volumes of wild-type medium was added gently by suspending cells up and 
down and transferred to a new 96-well plate or to 90mm plates already seeded with fibroblasts in 
case of ES-cells, or to a gelatin plate in case of COS-7 cells. 
 
 
6.1.7 COS-7 cell culture and transfection 
 
Culturing conditions: COS-7 cells were incubated (37°C and 5%CO2) in DMEM with 10% FCS, 
10µg/ml penicillin/streptomycin and 1mM sodium pyruvate.  
 
 
6.1.8 Embrynoic fibroblasts culture 
 
Culturing conditions: Mouse embryonic fibroblasts were cultured at 37°C and 5%CO2 in 
DMEM with 10% FCS and 10µg/ml penicillin/streptomycin and 0.03% glutamine.  
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6.1.9 Lipofection (DNA-Lipofectamine 2000), Electroporation of COS-7 and OLN93 cells  
 
DNA transfection into COS-7 and OLN93 cells was carried out by lipofection (DNA-
lipofectamine 2000, Invitrogen) or by electroporation accordingly. For lipofection the 
manufacturer´s protocol was followed. 5x106 OLN93 cells were electroporated with 0.8µg of 
linearized plasmid DNA in 0.8 ml of culture medium at 450 V and 250µF (0.4cm cuvette). 
Thereafter, cells were suspended in 10ml of medium and distributed at various concentrations 
(500-2000µl) to 90mm-cell culture round petri dishes seeded with fibroblasts.  
 
 
6.1.10 Stable selection of COS-7 or OLN93 cells  
 
After 24 hours of transfection (lipofectamine or electroporation), the wild-type medium was 
replaced with G418 containing wild-type medium for two weeks, for selection. The resistant 
COS-7 or OLN93 clones were picked under the microscope and transferred to a 24-well plate for 
further analysis. 
 
 
6.2 Molecular biology methods 
 
 
6.2.1 Plasmid-DNA preparation 
 
Plasmid mini-preparations of 3ml of overnight culture were performed according to the method 
of Birnboim (Birnboim, 1979). Plasmid maxi-preparations were carried out using Qiagen tip-500 
columns (Qiagen) according to the manufacturer's instructions. 
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6.2.2 Extraction of DNA from agarose gels 
 
DNA fragments were eluted from TBE (Tris-borate-EDTA) gels using NucleoSpin columns 
(Macherey & Nagel) as described in the manufacturer’s protocol. 
 
 
6.2.3 DNA isolation from ES cells or COS-7 cells 
 
Following protocol was employed for 96-well plate, 24-well plate, and as well as 90mm-petri 
dishes containing confluent ES cells, accordingly. The following procedure is described for 24-
well plate; ES cells were cultured until confluent on gelatin-coated 24-well plates. The medium 
was removed and cells were washed with 500µl of PBS and incubated overnight in 500µl of lysis 
buffer (100mM Tris/HCl [pH 8.5], 5mM EDTA [pH 8], and 200mM NaCl, 0.2%SDS) and 5µl of 
proteinase K (10mg/ml) at 37°C. Thereafter, the lysate was transferred to Eppendorf tubes and 
450µl of isopropanol was added. Incubated for 10 minutes at RT and centrifuged at 13,000rpm at 
4°C for 15 minutes. The DNA pellet obtained was washed with 70% ethanol of 500µl. After 
briefly drying, DNA was dissolved in 200µl of TE or 10mM Tris/HCl (pH 8) for 3 hours at 
55°C. Confluently grown ES cells on 90mm plates were trypsinized prior to the lysis for DNA 
preparation. 
 
 
6.2.4 Genomic DNA isolation from mouse tail 
 
For preparation of genomic DNA from mouse tails, about 0.5cm of tail tip biopsy was incubated 
overnight for digestion at 55°C at 1100rpm in 700µl of lysis buffer (50mM Tris-HCl pH 8.0, 
100mM EDTA, 100mM NaCl and 1%SDS) and 30µl of proteinase K (10mg/ml). DNA was 
precipitated with isopropanol, washed with 70% alcohol, and dissolved in 200µl TE. 
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6.2.5 Restriction analysis/digestion  
 
Plasmid DNA of 0.7-0.8µg was digested with 1U of the appropriate restriction endonuclease for 
1-2 hours at 37°C, according to the manufacturer’s protocol.  
 
 
6.2.6 Ligation 
 
Ligation was performed at 14°C in 20µl of volume overnight with 1U T4-DNA-ligase. PCR 
fragments ligation and cloning were performed with the TA Cloning Kit (Invitrogen) according 
to the manufacturer's instructions. 
Before ligation, 5'-end dephosphorylation was done by treating alkaline phosphatase (Roche) in 
order to prevent self ligation, according to the manufacturer’s protocol  
 
 
6.2.7 Preparation of Competent Cells and transformation of plasmid DNA 
 
Competent E. coli cells (DH5α) were prepared as previously described in Hanahan, 1983. 
 
Transformation of plasmid DNA into competent cells  
 
Frozen competent cells of 100µl were thawed on ice. Plasmid DNA of 3 to 5µl or ligation 
mixture of 20µl was gently mixed with the freshly thawed ice cold competent cells and incubated 
for 30 minutes on ice. A heat shock was given for 90 seconds at 42°C, 1000µl of ice cold LB 
medium was added and incubated for an hour at 37°C in a water bath. Cells were platted on LB 
plates containing appropriate antibiotics for selection. 
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6.2.8 Polymerase chain reaction (PCR) 
 
Reactions were performed in 20 or 50µl accordingly in a Peltier Thermal Cycler (Biozym). 
Template-concentration used in the range of: 5ng-50ng plasmid DNA, 1-5µg cDNA, 3ng-20ng 
PCR-fragments, 300ng genomic DNA. dNTP concentration: 100 nmol. Primer concentration: 
200 nmol. Taq polymerase (Expand High Fidelity PCR kit and the Long Template PCR kit, 
Roche): 1U/100µl. Reaction Buffer: 100mM Tris-Cl, pH 8.3, 500mM KCl, 15mM MgCl2, 
0.01%gelatin. 
Standard conditions of the PCR cycle were: 
Denaturation: 94°C, 1-3min 
Amplification: 94°C, 1-3min (denaturation), 50-70°C, 1-3 min (Annealing), 72 ° C, 1 min/kb 
(elongation) 
Elongation: 72 ° C, 10 min. 
 
Some of the standard PCR programs used in the present study: 
Desatgen-PCR program  Desatura-PCR program  RT-PCR program 
1= 94°C 2min    1=94°C 2min   1=94°C 2min 
2=94°C 15min   2=93°C 1min   2=93°C 1min 
3=60°C 30min   3=60°C 1min   3=60°C 1min 
4=68°C 7min    4=72°C 2:30min   4=72°C 2:30min 
5=go to 2 (for 9x)   5=go to 2 (for 30x)  5=go to 2 (for 30x) 
6=94°C 15min   6=72°C 10min  6=72°C 10min 
7=60°C 30min   7=4°C end   7=4°C end 
8=68°C 7min (+ 5sec/cycle)         
9=go to 6 (for 19x)   (Total of 3hours) 
10=68°C 7min   (used for SDM and for cDNA) 
11=4°C end 
 
(Total of 4hours 51min) 
Used for genomic DNA 
 
The annealing temperature was chosen about 3-5°C below the estimated melting temperature of 
the primers. The elongation time focused on the length of the expected amplicon is 
approximately 1 min/kb. PCR products were analyzed by gel electrophoresis on TBE agarose 
gels. 
For site directed mutagenesis, appropriate mutated primers were used in the normal PCR mixture 
with appropriate PCR temperature conditions based on primers point mutations. 
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6.2.9 DNA sequencing and Synthesis of oligonucleotide 
 
DNA Sequence analysis was done by the analytical department of the Center for Molecular 
Medicine Cologne (CMMC) using an ALF Express (Pharmacia) or an ABI-377 (Applied 
Biosystems). 
 
 Synthesis of oligonucleotides 
 
Oligonucleotides were synthesized by Metabion, Germany. 
 
 
6.2.10 RNA preparation 
 
RNA preparations were carried out using the TRIzol® LS Reagent (Life Technologies) 
according to the manufacturer's specifications. 
 
 
6.2.11 RT-PCR (Reverse transcription-PCR) 
 
For the preparation of cDNA, 5 or 10µg of RNA was used. 2µl of p (DN6) (50µM, Boehringer) 
was added and filled up with water to a volume of 31.5µl. The mixture was incubated for 10 
minutes at 70°C, and cooled for 2min on ice. 10µl of 5x RT buffer (Gibco/BRL), 4µl DTT 
(0.1M), 0.5µl RNAsin (Boehringer) and 2µl of dNTPs mix (10mM) were added and incubated 
for 10 minutes at 25°C, incubated at 42°C for two min, and 2µl of SuperScript-II (Gibco/BRL) 
was added. Total reaction time was 50 minutes at 42°C. Enzyme was denaturized by heating at 
70°C for 15 minutes. 
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Semi-quantitative PCR 
 
2µl of above reverse transcription derived cDNA was used for PCR and semi-quantified as 
follow:  
Semi-quantification (non-radioactive/cold): PCR product was separated on agarose gels and 
quantified with Image Quant software version 5.1 (Molecular Dynamics).  
Semi-quantification (radioactive/hot): Radioactive DNA labeled PCR were separated on a 
polyacrylamide gel dried and further analyzed by means of the gel phosphoimager SI 445 and 
semi-quantified by Image Quant software Version5.1 (Molecular Dynamics).  
 
 
6.2.12 Radioactive DNA labeling 
 
Radiolabeling of DNA fragments with [32P] dATP and [32P] dCTP (Amersham) was performed 
by means of the random primed DNA labeling kit (Boehringer) according to the manufacturer 
instructions. The removal of unincorporated nucleotides was performed by Probe Quant G-50 
Micro Columns (Amersham). 
 
 
6.3 Biochemical methods 
 
 
6.3.1 Protein quantification 
 
The protein was quantified by photometric determination using the BCA assay (Smith, 1985) 
(Pierce; Cu+ BCA protein complex) according to the manufacturer's instructions. 
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6.3.2 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
 
 
For protein expression analysis Bis-Tris gels (Invitrogen) of 4-12% concentration were used. 
After electrophoresis, gels were stained with Coomassie R-250 (0.3% in 10% acetic acid, 40% 
methanol), or silver (Blum et al., 1987).  
Myelin samples were separated under non-reducing conditions (sample buffer: 10% glycerol, 
125 mm Tris-Cl, pH 6.8, 4% SDS, and 0.02% bromophenol blue). For reducing the sample 
preparation, 4% β-mercaptoethanol was added. Samples were boiled for 3 min before 
application.  
 
 
6.3.3 Myelin preparation (Based on sucrose gradient separation) 
 
Myelin from freshly extracted mouse brains was prepared according to the Norton and Podulso 
(sucrose gradient) myelin extraction protocol (Norton and Podulso, 1973); Mouse brains were 
homogenized (Elvehjem Potter) in 12ml of 0.3M sucrose and gently overlaid on top of 0.85M 
sucrose in 30ml glass tube with a Pasteur pipette. After centrifugation at 10,000g at 4°C for 
20min, the white myelin interphase formed, was carefully collected into 30ml test tube and 
washed three times with double volume of water at 10,000 g, at 4°C for 20min. Thus obtained 
white precipitate (myelin) was dissolved in 500µl SDS buffer (non-reducing). 10-50µl aliquots 
were used for SDS-PAGE.  
 
 
6.3.4 Lipid analysis 
 
Total brain or myelin lipids extraction: Freshly obtained brains or isolated myelin from the brain, 
were subjected to ultra-turrax in CHCl3/methanol (2:1) and then incubated at 55°C in a water 
bath for lipid extraction. Extracts were centrifuged at 3000g for 4min. The precipitate was 
collected and again extracted with CHCl3/Methanol (1:1) and subsequently repeated with 
CHCl3/methanol (1:2). Thus obtained three supernatants in previous subsequent steps were 
collected, mixed and dried under N2 and further dissolved in 2-4 ml of CHCl3/Methanol (1:1). 
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For thin-layer chromatography analysis HPTLC silica gel 60 plates (Merck) were used. Lipid 
samples were applied and separated in different mobile phases: development of total lipids; 
CHCl3/methanol/H2O (65:25:4), and separation of gangliosides; CHCl3/methanol/NH4OH [2N] 
(60:35:4).  
For detecting or verifying the separated lipids, HPTLC plates were stained in different ways: for 
total lipid detection; ashing with 50% H2SO4 and incubation for 3-5min at 120°C, for 
phospholipids detection; Zinzadze staining (Dittmer and Lester, 1964), for glycolipids detection; 
Anthrone staining (Ledeen and Yu, 1982), for sialic acid containing lipids; orcinol staining 
(Ledeen, 1966), and for amine containing lipids; ninhydrin staining. 
Transesterification: Total lipids or separated individual phospolipids or sphingolipids were used 
for transesterification. First, the lipid extract was dried with N2.  To the dried lipid extract in an 
air tight flask or test tube, 2ml of Methonal.HCl was added and incubated at 80°C for 2 hours. 
An equal amount of water was added. Further, methyl esterified fatty acids were extracted in 
Hexane-Ether (1:1) of 2-4 ml.   
Fatty acid Silylation: MSTFA (N-methyl-trimethylsilyltrifluoroacetamide) of 30µl was added to 
150-200µl of fatty acid methly esters (FAME) for obtaining fatty acid silyl derivatives which 
were further characterized by GC-MS to identify long chain hydroxy-fatty acids. 
 
 
6.3.5 Gas Chromatography–Mass Spectrometry (GC-MS) 
 
Silylated transesterified lipids in CH2Cl2 solvent were used for GC-MS. The GC gradient ran 
from 160⁰C to 240⁰C, the temperature rise per minute was 4⁰C. GC separated individual 
compounds were detected by the mass spectrometer detector was based on individual fragments 
mass to charge ratio (M/Z). Obtained mass spectra with retention times of several individual 
fatty acids were analyzed manually by employing NEST database and Data analysis package 
(HP-MSD). 
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6.4 Immunological methods 
 
 
6.4.1 Western blotting 
 
Western Blot NuPage system (Invitrogen) was used according to the instructions of the 
manufacturer.  fter gel electrophoresis separation of the proteins they were transferred (3h, 
1mA/cm2, Sartoblot S II; Sartorius) onto a nitrocellulose membrane (Schleicher & Schuell) by 
semi-dry electroblotting method (Harlow and Lane, 1988).  
For blotting, the blot was constructed as follows:  
Cathode;  
Two Whatman filter paper soaked with 25 mM Tris pH 9.8, 20% methanol (40mM ε-
aminocaproic acid, optional); 
Gel, nitrocellulose membrane; 
Two Whatman filter paper soaked in 25 mM Tris, pH 10.4, and 20% methanol; 
Two Whatman filter paper soaked in 25 mM Tris, pH 10.4, 20% methanol. 
 
After transfer, the nitrocellulose membrane (Schleicher Schuell) was hybridized and blocked in 
TBS and 5% milk powder for 2 hours at RT or overnights in order to saturate free binding sites, 
then incubated with the first antibody in TBS and 5% milk powder for 1 hour at RT or over night 
at 4 ° C. Subsequently, the blot was washed three times for 10 minutes with TBS-T (TBS, 0.1% 
Tween 20) and incubated with the second antibody conjugated with peroxidase in TBS 5%milk 
powder for 1 hour. After three washings for 10 minutes each with TBS-T, the blot was 
developed. For peroxidase staining luminol detection reagent (100mM Tris/HCl [pH 8, 5], 
2.5mM luminol, 0.35mM coumaric, 0.01% H2O2) was used. The chemiluminescence was 
detected by X-ray films (Kodak, Fuji). 
Optimized concentrations of primary antibodies were used: anti-PLP serum: 1:400; anti-MBP 
antibody (monoclonal anti-mouse MBP Boehringer) 1:5000; anti-mouse serum MOG 1:1000, 
anti-rabbit serum MOG 1:10000). After washings, the secondary incubation with anti-rabbit or 
anti-mouse IgG peroxidase conjugate of FITC of CY3 (Sigma) for 1 h at room temperature in 
TBS and 5% milk powder was performed accordingly.  
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6.4.2 Immunostaining of cells 
 
Cells were plated on poly-L-lysine coated cover-slips. Fixation was done with 4% 
paraformaldehyde in PBS for 10 minutes, and washed one time and permeabilized with 
PBS/0.5% Triton X-100 for 15 minutes. Blocking of the cells was carried out for 1 hour at RT 
with 3% BSA in PBS. Washed with PBS for three times with 5 min incubation, and incubated 
for one hour with the primary antibody or anti-serum in the predetermined dilution in PBS and 
1% BSA. After washing four times with PBS, the second antibody was added and incubated for 
1 hour at RT. Double staining was performed accordingly with two types of fluorescent Cy3 
(red) or FITC (green) conjugated antibodies. Dapi counterstaining; Dapi was combined with the 
secondary antibody. Secondary antibody incubation was done in the dark. Preparations were 
washed three times with PBS/0.2% Triton X-100 and twice with PBS and then mounted on the 
microscopic slide. 
 
EGFP fluorescence analysis 
 
Cells were platted onto poly-L-lysine coated 96-well culture plate (Nunc) or on to cover slips 
present inside the 24 well plates. . Thus prepared plates were observed under a Zeiss Axioscop 
fluorescence microscope (with a filter for enhanced GFP; Chroma Analytical) and thus observed 
images were documented by using the Zeiss Axiovision documentation method. 
 
 
6.4.3 Mouse brain fixation for cryo-sectioning 
 
Mice were anesthetized with Nembutal and perfused through the left ventricle with 4% 
paraformaldehyde/2%glutaraldehyde in PBS. The brain was dissected, post-fixed for three hours 
in the perfusion solution and stored in 10ml of 0.5M sucrose overnight at 4°C. Further, tissue 
was embedded in OCT (Tissue Tek, Miles Scientific, Naperville), and sections of 8-10µm thick 
were obtained on microscopic slides (Superfrost Plus) at -20°C using a Cryotom (Bird, AS650). 
Sections were stored at -20°C.  
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6.4.3.1 Cryo-sections immunohistochemical staining 
 
Brain paraffin sections were fixed for 10minutes with 4%paraformaldehyde in PBS. Non-
specific binding sites were blocked with 3%BSA in PBS for 1 hour at room temperature. 
Incubation was performed with the primary antibody or anti-serum in 1%BSA/PBS for 2 hours at 
room temperature, washed three times with PBS (1%BSA/0.2%Triton X-100), incubated with 
the fluorescent conjugated secondary antibody for 1 hour at RT in the dark. After three washes 
with PBS/1% BSA, 0.2%Triton X-100, and slide was mounted with glycerol gelatin (2.5% 
DABCO, Merck) under a cover slip. 
 
 
6.4.4 Mouse brain fixation for paraffin sectioning  
 
Mice were anesthetized with Nembutal and perfused through the left ventricle with 4% 
paraformaldehyde/2%glutaraldehyde in PBS. Brains were dissected and post-fixed overnight in 
4% paraformaldehyde/2%glutaraldehyde at 4°C. Subsequently brains were embedded in an 
automated paraffin embedding machine according to the following program: 
1h 70% ethanol 
2h 70% ethanol 
2h 96% ethanol 
2h 96% ethanol 
3h 100% ethanol 
3h isopropanol 
3h xylene 
3h xylene 
3h xylene 
3h paraffin 
3h paraffin (with vacuum) 
 
Then the specimens were casted in a paraffin block and sliced appropriately on a microtome. 
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6.4.4.1 Paraffin sections immunohistochemical and hematoxylin-eosin staining 
 
Paraffin sections were de-waxed for 20 minutes in xylol and another 20 minutes in a fresh 
solution of xylol, then rehydrated prior to staining in a descending alcohol series (100% ethanol, 
90% ethanol, 70% and 50% ethanol) for 5 min each, washed with PBS and the procedure for 
immunohistochemical staining of cryosections followed. For hematoxylin/eosin staining, 
sections were placed in eosin for 5min and then rinsed in distilled water. They were then placed 
in hematoxylin for 5min, rinsed with distilled water and placed under tap water for 5minutes. 
Thereafter, the specimens were dehydrated in an ascending ethanol series (20%, 40%, 60%, 80% 
ethanol and 100% isopropanol) and mounted in mounting media (Merck). 
 
 
6.5 Electron microscopy 
 
Freshly dissected mouse optic nerve was post-fixed in 2%paraformaldehyde, 2%glutaraldehyde, 
0.15Mcacodylate buffer. Further embedding, sectioning, and visualization of electron 
micrographs were performed at the Institute of Anatomy, University of Cologne. 
 
 
6.6 Methods for generating mice mutants (Transgenic and Knock-in mutants) 
 
 
6.6.1 Mice maintenance 
 
Mice strains such as CD1 (outbred), and C57/Bl6 (with various genotypes such as plp-/-, fads2-/, 
plp-/-fads2-/-, PLP knock-in chimera; inbred), were maintained throughout the study in an 
artificial day-night cycle (lighting: 5:00 to 19:00 o’clock, darkness: 19:00 to 5:00 o’clock) with 
free access to food and water. 
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6.6.2 Microinjection 
 
DNA microinjection into the pronuclei was performed according to the protocol described in 
Hogan, 1986 as follows: Oocytes spending females (plp-/- mice) were super-ovulated two days 
prior to the microinjection with 5U gonadotropin, and after 46-48 hours stimulated with 5U 
human chorio gonadotropin and mated immediately with plp-/- male mice. After 24 hours of 
matting, females were selected by plug check. Then eggs were collected from the ampoule of the 
oviduct, and stored in M16 medium (16x Earle, 0.1 M pyruvate; 100x P/S, 37.5 x NaHCO3, 100 
mg of BSA) in an incubator (37°C and 5%CO2). Further, injections into the oocytes were done 
in M2 medium (Sigma) with a microinjector (Eppendorf type 5242, Jun-Air compressor model 
6) on micromanipulator stand (Leitz TypM), under the microscope (Wild/army castle). 
Successfully injected eggs were not disturbed for two to three hours and were re-implanted into 
the infundibulum of uterine tubes of a pseudo-pregnant mouse (one day pc; s mated with 
vasectomized males). 
 
 
6.6.3 Vasectomized males 
 
Vasectomized male mice at least two months old were used for obtaining pseudopregnant female 
mice for re-implantation of eggs (Hogan, 1986). 
 
 
6.6.4 Blastocyst injection 
 
Blastocysts were released into the DFH medium (DMEM; 10%FCS containing 20mM Hepes) 
from the uteri (3.5 days pc) dissected from at least four weeks old super-ovulated wild-type mice 
(C57/Bl6). After isolation of blastocysts in DF medium (DMEM, 10%FCS) further incubated at 
37°C and 4.8%CO2. The blastocysts injection was carried out in DFH-medium; Approximately 
20 ES cells were deposited on to the inner cell mass of blastocysts. The blastocyst injections 
were carried under the microscope (Leitz Axiovert 10) with a micromanipulator (Leitz TypM). 
Successfully injected blastocysts were cultured for one to two hours in M16 medium and re-
implanted into the uterine horn or uterus of 5-10 pseudopregnant mice (2.5 day pc; mated with 
vasectomized male) 
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6.7 Behavioral physiology 
 
Behavioral physiology tasks were modified from Wallace et al., 1980 and Morris, 1984. The 
open field and Morris water maze trail data were recorded in a software program (i.e., OFAKS 
and MWAKS), obtained from Neuroscience physiology department, Anatomy Institute, 
University of Cologne. Various genotypes i.e., wild-type (n=8), plp-/- (n=8), fads2-/- (n=8), and 
plp-/-fads2-/- (n=5) mice, of 5-months-old were used in the present study. 
 
 
6.7.1 Rotarod 
 
Animals were placed on a resting rod of diameter 3cm, and at a height of 30cm above the 
ground. Rod was rotated constantly at different speed intervals i.e., 16rpm, 24rpm, and 36rpm for 
2 min. Initially mice were trained for 2 days at 12 rpm. On day-3 and 4 the test was performed 
with three trails per day. The latency time of the mouse on the rotating rod in all trails were 
recorded and statistically analyzed. 
 
 
6.7.2 Horizontal rod and Grid task 
 
Three trails were performed on each day for three consecutive days. The first two days trails 
were used as a training period, whereas the third day performance was recorded and analyzed 
further.  
In horizontal rod task, mice were placed in the middle of a horizontal metal rod bridging two 
platforms (2X2, 80cm length), and the latency time of mice on the horizontal rod was recorded. 
Similarly in the grid task, mice were placed on the grid and rotated in 180°. Mice latency time on 
the grid was recorded with cutoff of 2 min and further readings were statistically analyzed.  
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6.7.3 T-maze 
 
Mouse was kept at the starting position in the T-Maze apparatus and after 5 seconds the start 
door was opened free to enter the left or right arm. Thus a series of 15 free-choice trails were 
carried out. The choice of the left or right arm chosen by the mouse was noted for further 
calculations. 
 
 
6.7.4 Open field 
 
The mouse was placed in the center of the open field apparatus (60 X 60 cm), the bottom 
platform being subdivided into 10 x 10 cm squares. During the test various behavioral patterns 
such as square crossings, time at corners and middle, number of groomings and rearings were 
recorded by the open field software (OFAKS). Each trail was recorded for 5 minutes. Animals 
were tested one time per day for five consecutive days.  
 
 
6.7.5 Morris water maze (Morris et al., 1984) 
 
Morris water maze experiments were performed in a circular polyethylene water tub (69 cm 
diameter and 22 cm height); with appropriate water levels, and a mouse resting platform of 
7.5cm diameter that was submerged approximately 0.5cm of water level and was placed in south 
quadrant at a constant place. The tub was virtually divided into four quadrants i.e., north, south, 
east, and west. The entire tub was monitored with a video cam and behavioral scoring exhibited 
by the mice was entered into Morris water maze software (MWAKS). Water temperature was 
maintained at 21 to 22°C. 
In all trails; mice were released into the Morris water maze tub from north quadrant, and 
platform location was in the south quadrant (in probe trail platform was removed). Mice 
swimming latency time, number of crossings along four quadrants (north, south, east, and west), 
mice location and total time duration in each quadrant was recorded.  
Procedure: After releasing the mouse into the water pool along the walls of the tub in north 
quadrant, the Morris water maze program was started immediately. When animals found the 
platform, they are allowed to rest for 10 sec, or if the animal cannot find the platform after 90 sec 
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of the trail they are directed towards the platform and allowed to sit on the platform for 20 sec. 
After each trail mice were dried with a towel and set back in the cage for 15-20 sec before the 
new trial begins. Thus, four trails were performed per day for 5 consecutive days. During the 
trail; escape latency, square crossings and swimming speed, and the time spend in each quadrant, 
were recorded by the Morris water maze program. On day 5; a probe trail was performed with no 
platform in the south quadrant, and the number of crossings on the position of the absent 
platform and the time spent in each quadrant was recorded and analyzed statistically. 
 
 
6.8 Bioinformatic programs and servers 
 
Lipid structural analysis/drawing   Lipidomic Gateway     
     (http://www.lipidmaps.org/tools/index.html) 
     (http://www.emolecules.com/)  
 
Kyte-Doolittle hydropathy plots   DNA star – Laser gene 
     (http://www.dnastar.com/t-products-lasergene.aspx)  
 
Hyrdorphobic properties prediction   SOSUI  
     (http://bp.nuap.nagoya-u.ac.jp/sosui/sosui_submit.html)  
 
Signal peptide prediction    SignalP v3.1      
     (http://www.cbs.dtu.dk/services/SignalP)  
 
Protein parameters      Expasy ProtParam 
(http://www.expasy.ch/tools/protparam.html)  
 
Domain prediction servers     SMART (http://smart.embl-heidelberg.de/) 
  
DNA editing tools   Sequence manipulation suite 
(http://www.bioinformatics.org/sms/index.html)  
 
Alignment programs    Mult Alin 
(http://multalin.toulouse.inra.fr/multalin/multalin.html)    
  ClustalX v1.81 
  Boxshade v3.21 
(http://www.ch.embnet.org/software/BOX_form.html)  
 
Phylogenetic program     Phylip v3.66 
 
Graphical software Vector     NTI (Invitrogen)  
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7 Appendix  
 
 
7.1 Plasmids used in the present study 
 
pBS 246   Gibco  
pBluescriptII SK(+)  Stratagene  
pcDNA3.1   Invitrogen  
PCR 2.1   Invitrogen  
pEGFPN-2   Clontech  
pIRES-EGFP   Clontech 
 
 
7.2 Oligonucleotides 
 
Primer Sequence Purpose  
PLPCDNA se 
GAC ATG GGC TTG TTG GTC GTC GGC TAG ATC 
TCT 
PLP/Dm20 
Cys 
PLPmut C24 s GCC ACT GGA TTG TCG TTC TTT GGA GTG GCA 
Site-
directed 
PLPmut C24 as TGC CAC TCC AAA GAA CGA CAA TCC AGT GGC mutagenesis 
PLPmut C32/34 s GCA CTG TTC TCG GGA TCG GGA CAT GAA GCT (SDM) 
PLPmut C32/34 as AGC TTC ATG TCC CGA TCC CGA GAA CAG TGC   
PLPmut C108 s TAC AAG ACC ACC ATC TGC GGC AAG GGC CTG   
PLPmut C108 as CAG GCC CTT GCC GCA GAT GGT GGT CTT GTA   
PLPmut C138/140 s GAG CGG GTG TCG CAT TCG TTG GGA AAA TGG   
PLPmut C138/140 as CCA TTT TCC CAA CGA ATG CGA CAC CCG CTC   
PLPmut  C168 s GTG TTT GCC TCT TCG GCT GTA CCT GTG TAC   
PLPmut C168 as GTA CAC AGG TAC AGC CGA AGA GGC AAA CAC   
PLPmut C183 s TGG ACC ACC TCT CAG TCT ATT GCC TTC CCT   
PLPmut C183 as AGG GAA GGC AAT AGA CTG AGA GGT GGT CCA   
PLPmut C200 s GGC AGT CTC TCT GCT GAT GCC AGA ATG TAT   
PLPmut C200 as ATA CAT TCT GGC ATC AGC AGA GAG ACT GCC   
PLPmut C219 s GGC AGG GTT TCT GGC TCC AAC CTT CTG TCC   
PLPmut C219 as GGA CAG AAG GTT GGA GCC AGA AAC CTT GCC   
PLPmut C227 s CTT CTG TCC ATC TCT AAA ACA GCT GAG TTC   
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PLPmut C227 as GAA CTC AGC TGT TTT AGA GAT GGA CAG AAG    
PLPmut as GAG CTC AGA ACT TGG TGC CTC GGC CCG TGA    
Fusion PLPXhoI se CTG GAA TTC GGC TCG AGA TGG GCT TGT TAG 
 
Transfection 
Fusion PLPPstI as GAA TTC GGC TTG ACT GCA GAA CTT GTT GCC  constructs 
Human Nestin se GAC TTC CAA GGC CTC TTC TAG CCT GGA   
Hum.Nestin Ex II se TCG GCA GCA GCT GGC GCA CCT CAA GAT   
MBP Prom43-20 se ACC AGA TCT TAT CGA TCA CCG TGG CTT   
MBP Prom1286-1309 
a.se GGA CTC TGA GAT CGA TTC TTT GAA GGT   
MBP No RS a.se GTC TGC TGT GTG CTT GGA GTC TGT CAC   
MBP No RS se ACT GCG GCT TAC AGA GGA GCC AGA TCC   
Ires2-egfp 1980 se GTA CAA GTA AAG TGG ACG GGA CTC TAG ATC   
Ires2-egfp 1980 a.se GAT CTA GAG TCC CGT CCA CTT TAC TTG TAC   
pIRES-EGFP 2k a.se ACG CCT TAA GAT ACA TTG ATG AGT TTG GAC A   
Pre PLP Int-Ia sense 
primer CCC TCT GTA GCC AAT TAC TCT ATT TCC TGC 
Knock-In 
construct 
Pre PLP intron-Ib 
sense CTA TAG TTA GAA ATA GTG TGA CTA TTT ACA   
PLP EX-IV antisense 
primer AGG GAA GGC AAT AGA CTG AGA GGT GGT CCA 
  
 
PLP Intron-VII as ATC GAT CTT TCA CTC CTC CTC GAG TTG CAG   
GPLP start EX VII se GAGAGTCTTGCAGTGATTAATCTCTCTCTG   
3’ neo ‘sense primer’ GCG CAT CGC CTT CTC TCG CCT TCT TGA   
Infusion GPLP ExVII 
XhoIStuI (43 bs) 
CCA GCT GCA ACT CGA GTC GCA GAG GAG TGA 
AAG GCC TAA TTG A   
Infusion GPLP IntVII 
XhoI a.se (43bs) 
CAT TAA TTA ACT CGA GTA TGC ACA GAA TGA 
ATG CAT GTC TCT TTG   
5’ Neo ‘antisense 
primer’ TGC GAA TCG GGA GCG GCG ATA CCG TA   
Intron-I ‘as.p’ TCT GTT TTG CGG CTG ACT TTG 
plp-/- fads2 
-/- mice 
5’ UTR ‘s.p’  GGA GAG GAG GAG GGA AAC GAG   genotyping 
Neo ‘as.p’ TTG GCG GCG AAT GGG CTG AC   
5’UTR ‘s.p’ (Fads2) CCT TCC TTG TTC CAG ACA CGG TCT CAA GAG 
ex-I ‘a.p’ (Fads2) CGT AGC ATC TTC TCC CGA ATA GTG TCC GAT 
NCAM 140 s CCA TCA GAC ACT ATC TGG TC RT-PCR 
NCAM 140 as TCAGGAAGTAGCAGGTGATG   
NCAM 120 s CCT GAA GAG CAT CCA GTA CA   
NCAM 120 as ATG AAT TCC AAG GAC TCC TG   
RT-MAG s TGC TCA CCA GCA TCC TCA CG   
RT-MAG as AGC AGC CTC CTC TCA GAT CC   
RT-MOG s CCA AGA GGA GGC AGC AAT GG   
RT-MOG as GTT GTA GCA GAT GAT CAA GG   
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7.3 Abbreviations 
 
AA   Arachidonic acid 
cDNA   complementary DNA  
CMV   Cytomegalovirus  
CoA   Coenzym A 
CGT   UDP-galactose:ceramide galactosyltransferase 
DM   Double mutant (plp-/-fads2-/- knock out mouse mutant) 
DMSO   Dimethyl sulfoxide  
DNA   Deoxyribonucleic acid 
DMEM  Dulbecco’s modified eagle medium 
DHA   Docosahexaenoic acid 
dNTP   Deoxynucleoside Triphosphate 
MBP s TAC CTG GCC ACA GCA AGT AC   
MBP as GTC ACA ATG TTC TTG AAG    
OMgp s GCA GCA GCT GCA ACT CTA AC   
OMgp as GAA GCA TTT ACT TTC CAA GCA   
m vimentin s ACT ATT GGC CGC CTG CAG GAT GAG ATC CAA   
m vimentin as CAA GGT CAT CGT GAT GCT GAG AAG TCT CAT   
FADS2 se ATG GGG AAG GGA GGT AAC CAG GGA GAG GG   
FADS2 as TCA TTT ATG GAG GTA AGC ATC CAG CCA CAG    
FADS1 s GGT ATA TTT TCT ATT ATTG TGG TTC AGC GGA   
FADS1 as TAA ACA ATG TCC GCG AAG GCT GTG AGC AGG    
FADS3 s TGA AGT TGA AAA TCT GGC GTA CAT GCT GGT   
FADS3 as ATG TCG CCA GAC TTC TTC AGG GAC CCG ATG   
SCD1 s CAT GCT CCA AGA GAT CTC CA    
SCD1 as CGG CTG TGA TGC CCA GAG CG   
SCD2 s TTG AAA AGA GTT CTC ACC ACT GGG GAG CAG   
SCD3 s TAT TGA GGG CAT TGG AGC CGG AGT CCA TCG   
SCDx as CTT GTA GTA CCT CCT CTG GAA CAT CAC CAG   
CGT s GAA ATT CAC AAG GAT CAA CC   
CGT as GTC CAT TAA CTG TGC TAT GC   
CNX43 1021 s ACC AAC GGC CCC ACT CTC ACC TAT GTC TCC   
CNX43 1350 as TAA ATC TCC AGG TCA TCA GGC CGA GGT CTG   
GAPDH s GAC CAC CCT GTT GCT GTA GC   
GAPDH as GAG CTG AAC GGG AAG CTC AC   
Beta-actin s TAT GGA ATC CTG TGG CAT CCA TGA AAC TAC   
Beta-actin as GGT GTA AAA CGC AGC TCA GTA ACA GTC CGC 
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E. coli   Escherichia coli 
EDTA   Etylene diamino tetra-acetic acid 
EGFP   enhanced green fluorescent protein  
ER   endoplasmic reticulum 
EPA   Eicosapentaenoic acid 
ES-cell  Embryonic stem cell 
FAD   Fatty acid desaturase                            
Ganc   Ganciclovir sodium 
GAPDH  Glyceraldehyde 3-phosphate dehydrogenase 
HGPRT  Hypoxanthin-Guaninphosphoribosyltransferase  
HRP   Horseradish peroxidase 
IDL   Inter dense line (Myelin membrane) 
IgG   Immunoglobulin G  
Kb   Kilobase  
kDa   Kilodalton 
LIF   leukemia inhibitory factor 
loxP   locus of X-over P1 
M   Molar 
mM   millimolar 
mg   milligram 
min   minute 
ml   milliliter 
MBP   Myelin basic protein 
MDL   Major dense layer (Myelin membrane) 
MOG   Myelin oligodendrocyte protein 
MAG   Myelin-associated glycoprotein 
MSTFA  N-Methyl-N-trimethylsilyl-trifluoracetamid 
MWM   Morris water maze 
ng   nanogram 
nM   nanomolar 
Neo   neomycin phosphotransferase 
NCAM  Neural Cell Adhesion Molecule 
O.D   optical density 
OMgP   Oligodendrocyte-myelin glicoprotein 
PCR   polymerase chain reaction 
PLP   proteolipid protein 
PBS   phosphate-buffered saline 
RNA   Ribonucleic acid 
SCD   Stearoyl-CoA desaturase 
SDS   Sodium dodecyl sulphate 
SDS-PAGE  SDS-polyacralamide gel electrophoresis 
Sec   Second  
TK   Thymidine kinase 
TBE   Tris buffer EDTA 
TBS   Tris buffer saline 
TBS-T   TBS-Tween 
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Tris   tris(hydroxymethyl)aminomethane 
U   Unit  
UDP   Uridine diphosphate 
WT   Wild-type 
µg   microgram 
µl   micro liter 
µm   micromolar 
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Zusammenfassung 
 
 
Myelinscheiden des zentralen Nervensystems werden von Oligodendrozyten gebildet und 
bestehen zu 80% aus Lipiden und zu 20% aus Proteinen. Die Myelinbildung stellt einen 
komplexen und konservierten Prozeß dar. Kommt es zu pathologischen Veränderungen im 
Ablauf, die eine fehlerhafte Zusammensetzung der Protein- oder Lipidkomponente bedingen, 
kann dies zu funktionalen Störungen des Myelins führen. 
Die hier vorgestellte Arbeit kann in zwei Kerngebiete aufgeteilt werden: 
A) Die Untersuchung der Rolle der Cys-Reste des Proteolipid Protein (PLP/Dm20) auf die 
Myelinstruktur und –funktion. 
B) Die Rolle von PLP/Dm20 und den mehrfach ungesättigten Fettsäuren (polyunsaturated fatty 
acids, PUFAs) bei der Morphologie und der Physiologie des Myelins im ZNS. 
 
A) Das PLP ist stark konserviert und macht den größten Proteinanteil des ZNS Myelins aus. 
Punktmutationen im PLP sind bekannt dafür, verschiedene Formen von PMD/SPG2 
dysmyelinisierende Leukodystrophien in Mensch und Maus zu verursachen. Einige 
Punktmutationen in PLP werden im Zusammenhang mit einem gestörten Plasmamembran 
transport von PLP/Dm20 in den Oligodendrozyten und dem jeweiligen Krankheitsgrad der PMD 
diskutiert. 
PLP und seine Isoform Dm20 besitzen 14 beziehungsweise 12 Cys-Reste, die in die 
posttranslationale S-Acylierung und die Bildung von zwei Disulfid Brücken einbezogen sind. 
Diese Arbeit sollte zum besseren Verständnis der Bedeutung der Cys-Reste in PLP/Dm20 
führen. Dafür wurde eine PLP/Dm20 Mutante verwendet, in der die Cys- durch Ser-Reste 
ausgetauscht wurden (i.e. Mut-PLP/Dm20). In silico Analysen zeigten, dass Mut-PLP und Mut-
Dm20 sowohl verminderte Transmembran-Strukturen als auch reduzierte hydrophobe 
Eigenschaften besitzen, während mit Hilfe der in vivo und in vitro Analysen ein verringertes 
Zelloberflächen Targeting nachgewiesen wurde. 
Um die Rolle von Mut-PLP in der Myelinisierung früher embryonaler Stadien zu verstehen, 
sollte durch Vorkerninjektion eine Mauslinie generiert werden, die einen Nestin Enhancer und 
ein MBP Promotor regulatorisches Element zusammen mit der Mut-PLP cDNA trägt. Zudem 
sollte eine knock-in Mausmutante generiert werden, die keine Disulfidbrücken in PLP/Dm20 
trägt, um die Rolle der Disulfid-Brücken in PLP zu verstehen. 
 
B) PLP ist ein intergrales Myelinmembranprotein, PUFAs sind Bestandteile von Phospholipiden, 
den beiden kritischen strukturellen Komponenten der ZNS Myelinmembran. Zum besseren 
Verständnis der signifikanten Rolle von PLP und den PUFAs und deren Auswirkung auf das 
ZNS wurden Untersuchungen an der plp-/- fads-/- transgenen Doppelmutante (DM) 
durchgeführt. Die DM wurde durch Kreuzung generiert und auf genomischer-, sowie 
Transkriptions- und Translationsebene bestätigt. 
Die DM zeigt einen schweren kataleptischen Zustand mit einem milden Tremor und Krämpfen 
ab dem fünften Lebensmonat, sowie eine drastisch verkürzte Lebensdauer im Vergleich zu den 
Einzelknockout Mutanten (plp-/- und fads-/-) und dem Wildtyp. 
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Die Fettsäureanalyse des Gehirns der DM und des ZNS Myelins zeigten nur teilweise 
verminderte Docosahexaensäure (DHA) Konzentration (40-50%), was andeutet, dass DHA stark 
konserviert ist und deswegen in den Membranstrukturen des ZNS zurückbehalten wird. 
Erstaunlicherweise wurde eine ungewöhnliche PUFA, die Eisosatriensäure (20:3) gefunden, die 
möglicherweise die nicht mehr vorhandene Arachidonsäure ersetzt. Weitere Analysen des DM 
Genexpressionsprofils zeigten keine signifikanten Unterschiede der Myelinproteine und 
Desaturasen. Das erlaubt den Schluß, dass die Abwesenheit von PLP und den PUFAS zu  keiner 
Veränderung der myelinbezogenen Proteine führt.  
 
Die Morphologie des ZNS Myelins ist in der DM Maus stark verändert, und weist  
Hypomyelinsierung und Verlust der Kompaktheit des Myelins auf.  
Das retinale Pigmentepithel zeigt keinerlei morphologischen Veränderungen. Die durch das ERG 
nachgewiesene retinale Funktion zeigt einen Abfall im a-Wellen Signal, was auf Veränderungen 
der visuellen Funktionen hinweist.  
Verhaltensphysiologische Studien, die unter anderem mit Hilfe des Rota Rod und der Water 
Maze durchgeführt wurden, zeigten partielle, aber keine signifikanten Defekte in der 
neuromotorischen Koordination/Funktion. Durch die Water Maze wurden zudem signifikante 
Defekte in den kognitiven Fähigkeiten (i.e. die Raumkognition/Lernfähigkeit und 
Erinnerungsvermögen) nachgewiesen. Die Veränderungen in der Verhaltensphysiologie und der 
reduzierten Lebensdauer korrelieren möglicherweise mit der gestörten Myelinmorphologie und 
der Hypomyelinisierung des ZNS. 
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Abstract 
 
 
The CNS myelin sheath is an extension of the oligodendrocyte plasma membrane and is 
composed of 80% lipid and 20% protein. Myelin formation is a very sophisticated and highly 
conserved process, any disturbance of myelin protein or lipid composition has a strong impact on 
myelin biogenesis and myelin phenotype, which often results in CNS myelin pathology. The 
work presented here is divided into two parts: A. An investigation of the role of proteolipid 
protein (PLP/Dm20) Cys residues in myelin structure and function, and B. The role of 
PLP/Dm20 and polyunsaturated fatty acids (PUFAs) in CNS myelin morphology and CNS 
physiology.  
A. PLP is highly conserved and is the most abundant protein of CNS myelin. Also, point 
mutations in PLP are known to cause a variety of mild to severe PMD/SPG2 dysmyelinating 
leukodystrophies both in human and in mice. Some PLP point mutations are directly correlated 
to the perturbed plasma membrane trafficking of PLP/Dm20 in oligodendroyctes and correlate 
with the severity of PMD. PLP and its isoform Dm20 have 14 and 12 Cys residues, respectively, 
and are involved in post-translational S-acylation and the formation of two disulfide bridges. The 
work presented within this thesis furthers the understanding of the role of the Cys residues in 
PLP/Dm20. We analysed PLP/Dm20 Cys residue function by replacing Cys residues in 
PLP/DM20 with Ser residues (i.e., Mut-PLP/Dm20). In silico analyses predicted that the Mut-
PLP and Dm20 have impaired transmembrane structure and reduced hydrophobic properties, 
supported by our in vivo and in vitro analysis which revealed perturbed cell surface targeting of 
the mutant proteins. Furthermore, in order to understand the role of Mut-PLP in CNS at early 
embryonic stages, a transgenic mouse mutant is being generated via pronuclear injection of a 
transgene composed of a Nestin enhancer and MBP promoter regulatory elements along with 
Mut-PLP cDNA, on a PLP negative genomic background. In addition, to understand the role of 
di-sulfide bridges in PLP; a knock-in mouse mutant is being generated in which the disulfide 
bridges of PLP/Dm20 have been deleted.  
B. PLP is an integral myelin membrane protein, and PUFAs are constituents of phospholipids, 
which are critical structural components of the CNS myelin membrane. In this thesis, we have 
expanded the understanding of the significant role of PLP and PUFAs and their impact in the 
CNS by phenotyping the plp-/-fads2-/- double knock-out mouse model (DM). The DM has been 
generated and validated on a genomic, RNA and protein level confirming lack of PLP and Fads2 
which is a key enzyme for endogenous PUFAs synthesis. The DM exhibited a profound 
behavioral cataleptic state with mild tremor and seizures starting from 5 months age, and had a 
significantly reduced life span, compared to the single mutants (plp-/- and fads2-/-) and wild-
type counterparts.  
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In the brain and CNS myelin of the DM mice, PUFAs analysis revealed only partially depleted 
docosahexanoic acid (DHA) levels (40-50%) suggesting that DHA is highly regulated and/or is 
compensated for depleted PUFAs and was retained tenaciously in membrane structures of the 
CNS. Intriguingly, an unusual PUFA, eicosatrienoic acid (20:3) was detected, which may 
substitute for the observed depletion of arachidonic acid. Further analyses of the gene expression 
profile in the DM brain revealed no significant differences among myelin membrane proteins, 
desaturases and other myelin specific proteins, thus suggesting no alteration of these proteins in 
the absence of PLP and PUFAs.  
The DM mice showed a massive alteration in morphology of the CNS myelin manifesting as 
hypomyelination and a loss of myelin compaction around axons. In retinal electron micrographs, 
the retinal pigment epithelium (RPE) region showed no major significant morphological 
alterations. Retinal function, as assessed by ERG, revealed a decrease in a-wave signals 
suggesting defects in visual functions. Behavioral physiology studies, as assessed by the rota-rod 
task and Morris water maze and other similar tasks, showed partial but significant defects in 
neuromotor coordination/functions. The Morris water maze also revealed significant defects in 
cognitive ability (i.e., spatial acquisition/learning and in the reference memory). Alterations in 
behavioral physiology and the reduced lifespan in DM mice may be correlated with the disrupted 
myelin morphology and hypomyelination of CNS.   
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